Document:

Exhibit 10.3

 

ASSET PURCHASE AGREEMENT

 

among

 

CONCORDIA PHARMACEUTICALS INC., S.À.R.L.,
BARBADOS BRANCH,

 

TELIGENT JERSEY LIMITED

 

and

 

IGI LABORATORIES, INC.

 

DATED AS OF OCTOBER 5, 2015

 

    Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

TABLE OF CONTENTS

 

	 	 	Page
	 	 	 
	ARTICLE I
	 
	DEFINITIONS AND TERMS
	 	 	 
	Section 1.1	Definitions	1
	Section 1.2	Other Definitional Provisions	9
	 	 	 
	ARTICLE II
	 
	PURCHASE AND SALE
	 	 	 
	Section 2.1	Purchase and Sale of Assets	10
	Section 2.2	Consents	10
	Section 2.3	Excluded Assets	11
	Section 2.4	Assumption of Liabilities	12
	Section 2.5	Excluded Liabilities	13
	 	 	 
	ARTICLE III
	 
	CLOSING
	 	 	 
	Section 3.1	Purchase Price	13
	Section 3.2	Closing	13
	Section 3.3	Closing Deliverables	14
	 	 	 
	ARTICLE IV
	 
	REPRESENTATIONS AND WARRANTIES OF SELLER
	 	 	 
	Section 4.1	Organization and Qualification	15
	Section 4.2	Authority; Binding Effect.	15
	Section 4.3	No Conflicts	15
	Section 4.4	Governmental Authorization; Consents	16
	Section 4.5	Absence of Material Changes	16
	Section 4.6	No Litigation	16
	Section 4.7	Compliance with Laws.	17
	Section 4.8	Product Registrations; Regulatory Compliance.	17
	Section 4.9	Intellectual Property.	18
	Section 4.10	Assets	19
	Section 4.11	Contracts	19
	Section 4.12	Inventory	20
	Section 4.13	Product Liability	20
	Section 4.14	Brokers	21
	Section 4.15	Taxes	21
	Section 4.16	No Other Representations or Warranties	22

 

    -i- 
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

	ARTICLE V
	 
	REPRESENTATIONS AND WARRANTIES OF PURCHASER
	 	 	 
	Section 5.1	Organization and Qualification	22
	Section 5.2	Authority; Binding Effect	22
	Section 5.3	No Conflicts; Consents	23
	Section 5.4	Governmental Authorization	23
	Section 5.5	No Litigation	24
	Section 5.6	Condition of the Purchased Assets	24
	Section 5.7	Brokers	25
	 	 	 
	ARTICLE VI
	 
	COVENANTS
	 	 	 
	Section 6.1	Bulk Transfer Laws.	25
	Section 6.2	Books and Records	26
	Section 6.3	Insurance	26
	Section 6.4	Trade Notification	26
	Section 6.5	Tax Allocation	27
	Section 6.6	Tax Treatment	27
	Section 6.7	FDA Letters.	27
	Section 6.8	Regulatory Responsibilities	28
	Section 6.9	Cooperating	29
	Section 6.10	Further Assurances	29
	Section 6.11	Wrong Pockets	30
	Section 6.12	Know-How License	30
	Section 6.13	IGI Purchaser Guarantee	31
	 	 	 
	ARTICLE VII
	 
	INDEMNIFICATION
	 	 	 
	Section 7.1	Indemnification by Seller	31
	Section 7.2	Indemnification by IGI Purchaser	32
	Section 7.3	Notice of Claims	32
	Section 7.4	Third Party Claims	33
	Section 7.5	Expiration	34
	Section 7.6	Limitations on Indemnification.	34
	Section 7.7	Losses Net of Insurance, Etc.	35
	Section 7.8	Reimbursement	36
	Section 7.9	Sole Remedy/Waiver	36
	 	 	 
	ARTICLE VIII
	 
	MISCELLANEOUS
	 	 	 
	Section 8.1	Notices	36

 

    -ii-
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

	Section 8.2	Amendment; Waiver	38
	Section 8.3	Successors and Assigns; No Third Party Beneficiaries	38
	Section 8.4	Entire Agreement	39
	Section 8.5	Parties in Interest	39
	Section 8.6	Confidential Information	39
	Section 8.7	Expenses, Transfer Taxes and Property Taxes	40
	Section 8.8	Schedules	40
	Section 8.9	Governing Law; Jurisdiction	41
	Section 8.10	WAIVER OF JURY TRIAL	42
	Section 8.11	Counterparts	42
	Section 8.12	Headings	43
	Section 8.13	Severability	43
	Section 8.14	Mutual Drafting	44

 

SCHEDULES OTHER THAN DISCLOSURE SCHEDULES

 

	1.1(a)	 	IGI Purchased Assets
	1.1(b)	 	Intellectual Property Licenses
	1.1(c)	 	Knowledge of Purchaser
	1.1(d)	 	Knowledge of Seller
	1.1(e)	 	Products and Product Registrations
	1.1(f)	 	Retained Products
	1.1(g)	 	Shared Contracts
	1.1(h)	 	TJL Purchased Assets
	2.1(i)	 	Contracts Solely Relating to the Products
	2.1(ii)	 	Purchase Orders

 

EXHIBITS

 

	EXHIBIT A	 	IGI Assignment and Assumption Agreement
	EXHIBIT B	 	IGI Bill of Sale
	EXHIBIT C	 	Labeled Inventory Partial Assignment Agreement
	EXHIBIT D	 	Receipt
	EXHIBIT E	 	Teligent Assignment and Assumption Agreement
	EXHIBIT F	 	Teligent Bill of Sale
	EXHIBIT G 	 	Transition Services Agreement
	EXHIBIT H	 	List of Instruments and Documents Delivered at Closing by Seller
	EXHIBIT I	 	List of Instruments and Documents Delivered at Closing by IGI Purchaser
	EXHIBIT J	 	List of Instruments and Documents Delivered at Closing by TJL Purchaser

 

    -iii- 
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

ASSET PURCHASE AGREEMENT

 

This Asset Purchase Agreement
is made and entered into as of the 5th day of October 2015, by and between Concordia Pharmaceuticals Inc., S.à.r.l.,
Barbados Branch, the Barbados branch of Concordia Pharmaceuticals Inc., a société à responsabilité
limitée (private limited liability company) duly organized and validly existing under the laws of the Grand-Duchy of
Luxembourg, with a share capital of USD 5,000,000, having its registered office at 8-10 Avenue de la Gare – L-2610 Luxembourg,
Grand-Duchy of Luxembourg and in the process of registration with the Registre de Commerce et des Sociétés,
Luxembourg (Luxembourg Trade and Companies Register) (formerly known as and successor-in-interest to Concordia Pharmaceuticals
Inc., an international business company organized under the laws of Barbados) (“Seller”), on the one hand, and
IGI Laboratories, Inc., a corporation organized under the laws of Delaware (“IGI Purchaser”), and Teligent Jersey
Limited, a company incorporated in Jersey with registration number 119574 and having its registered office at 47 Esplanade, St.
Helier, Jersey JE1 0BD (“TJL Purchaser,” and together with IGI Purchaser, “Purchasers”, and
each, a “Purchaser”), on the other hand.

 

WITNESSETH:

 

WHEREAS, Seller
desires to sell, transfer and assign to IGI Purchaser, and IGI Purchaser desires to acquire and assume from Seller, all of the
Inventory, the IGI Assumed Contracts and all of the Assumed Liabilities associated therewith, all as more specifically provided
herein; and

 

WHEREAS, Seller
desires to sell, transfer and assign to TJL Purchaser, and TJL Purchaser desires to acquire and assume from Seller, all of the
TJL Purchased Assets, and all of the Assumed Liabilities associated therewith, all as more specifically provided herein.

 

NOW, THEREFORE,
in consideration of the foregoing and the representations, warranties, covenants and agreements contained herein, the parties hereby
agree as follows:

 

ARTICLE
I

 

DEFINITIONS
AND TERMS

 

Section
1.1        Definitions. As used in this Agreement, the following terms shall have the meanings set forth or as referenced
below:

 

    

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

“Affiliate”
means with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common control with,
such Person at any time during the period for which the determination of affiliation is being made.

 

“Agreement”
means this Agreement, as amended or supplemented from time to time in accordance with the terms hereof.

 

“Ancillary Agreements”
means, collectively, the IGI Assignment and Assumption Agreement, the TJL Assignment and Assumption Agreement, the IGI Bill of
Sale, the TJL Bill of Sale, the Labeled Inventory Partial Assignment Agreement, the Transition Services Agreement and each other
agreement, document, instrument and/or certificate to be executed by Purchasers or Seller in connection with the transactions contemplated
by this Agreement.

 

“Assignment
Consent” has the meaning set forth in Section 2.2(a).

 

“Assumed Contracts”
means, with respect to IGI Purchaser, the IGI Assumed Contracts, with respect to TJL Purchaser, the TJL Assumed Contracts, and
with respect to Seller, the IGI Assumed Contracts and the TJL Assumed Contracts.

 

“Assumed Liabilities”
has the meaning set forth in Section 2.4.

 

“Books and Records”
means financial, accounting, operating data and records, including (a) inventory records, product specifications, customer lists,
cost and pricing information, supplier lists, customer literature, quality control records and manuals; (b) product development
files, and records and stability and clinical studies; (c) data relevant to the manufacturing of a Product; (d) Regulatory Documentation;
and (e) Promotional Materials, in each of the foregoing clauses (a) through (e), solely to the extent (i) in Seller’s physical
possession or control and (ii) of the portions thereof exclusively related to the Purchased Assets (including all data and other
information stored on discs, tapes or other media); provided, however, that Seller may retain a copy of (A) all such
Books and Records to the extent necessary for reporting, regulatory, Tax, accounting or litigation purposes, (B) any correspondence
to, with or from any Person in connection with the Excluded Assets, the Excluded Liabilities or as otherwise required by applicable
Law and (C) any books and records relating to the Excluded Assets or Excluded Liabilities.

 

“Business Day”
means any day other than a Saturday, a Sunday or a day on which commercial banks in New York City or the parish of St. Michael,
Barbados, are authorized or obligated by applicable law or executive order to close.

 

“Cap”
has the meaning set forth in Section 7.6(b).

 

“Closing”
means the closing of the transactions described in Article III pursuant to and in accordance with the terms of this Agreement.

 

“Closing Date”
has the meaning set forth in Section 3.2.

 

“Confidentiality
Agreement” means the Confidentiality Agreement between Seller and Purchaser, dated July 9, 2015, as amended or supplemented
from time to time.

    -2- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

“Consideration”
has the meaning set forth in Section 6.5.

 

“Contract”
means any binding written contract, agreement, lease, license or commitment.

 

“Copyrights”
means all copyrights and registrations and applications therefor, and all renewals, extensions, restorations and reversions thereof.

 

“Distribution
Activities” has the meaning set forth in Section 6.2.

 

“Excluded Assets”
has the meaning set forth in Section 2.3(a).

 

“Excluded Liabilities”
has the meaning set forth in Section 2.5.

 

“Exploitation”
(including, with correlative meanings, the terms “Exploit” and “Exploited”) means sale.

 

“FDA”
means the U.S. Food and Drug Administration or a successor thereto.

 

“FDCA”
means the U.S. Federal Food, Drug and Cosmetic Act of 1938, as amended and implementing regulations.

 

“FTC”
means the U.S. Federal Trade Commission or a successor thereto.

 

“Fundamental
Representations” has the meaning set forth in Section 7.5.

 

“Governmental
Authority” means any supranational, national, federal, state or local judicial, legislative, executive or regulatory
authority.

 

“Governmental
Order” means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any
Governmental Authority.

 

“Health Care
Laws” means all applicable health care Laws and Governmental Orders, including the federal Anti-Kickback Statute, 42
U.S.C. § 1320a-7b(b), the Anti-Inducement Law, 42 U.S.C. § 1320a-7a(a)(5), the civil False Claims Act, 31 U.S.C. §§
3729 et seq., the administrative False Claims Law, 42 U.S.C. § 1320a-7b(a), the Health Insurance Portability and Accountability
Act of 1996, 42 U.S.C. §§ 1320d et seq., as amended by the Health Information Technology for Economic and Clinical
Health Act, 42 U.S.C. §§ 17921 et seq., the exclusion Laws, 42 U.S.C. § 1320a-7, the FDCA and related FDA
regulations, Medicare, Title XVIII of the Social Security Act, and Medicaid, Title XIX of the Social Security Act.

 

“IGI Assignment
and Assumption Agreement” means the assignment and assumption agreement, dated as of the Closing Date, attached as Exhibit
A to this Agreement.

 

“IGI Assumed
Contracts” has the meaning set forth in Schedule 1.1(a).

 

    -3- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

“IGI Bill of
Sale” means the bill of sale, dated as of the Closing Date, attached as Exhibit B of this Agreement.

 

“IGI Purchase
Orders” has the meaning set forth in Schedule 1.1(a).

 

“IGI Purchaser”
has the meaning set forth in the Preamble of this Agreement.

 

“IGI Purchased
Assets” means the assets set forth on Schedule 1.1(a), it being understood that the IGI Purchased
Assets do not include the Excluded Assets.

 

“Indemnified
Party” has the meaning set forth in Section 7.3(a).

 

“Indemnifying
Party” has the meaning set forth in Section 7.3(a).

 

“Indemnity Threshold”
has the meaning set forth in Section 7.6(a).

 

“Independent
Accountant” has the meaning set forth in Section 6.5.

 

“Intellectual
Property” means all worldwide Copyrights, Patents and Trademarks, and Trade Secrets.

 

“Intellectual
Property Licenses” means the licenses identified in Schedule 1.1(b).

 

“Inventory”
means (a) all raw materials, active pharmaceutical ingredients, excipients, intermediaries, reagents, supplies, packaging, work
in progress and finished goods owned by Seller and (b) finished goods, whether imported, procured from contract manufacturers,
or otherwise, that are in Seller’s physical possession or control, in each case, as of the Closing Date and that are exclusively
related to the Products and are set forth in Section 4.12 of the Seller Disclosure Schedule.

 

“Inventory Value”
means the value of the Inventory as of the Closing Date, which the Parties hereby agree is $1,000,000.

 

“Knowledge of
Purchaser” means the current actual (but not constructive or imputed) knowledge, without inquiry or investigation, of
any of the individuals listed on Schedule 1.1(c).

 

“Knowledge of
Seller” means the current actual (but not constructive or imputed) knowledge, after reasonable inquiry, of any of the
individuals listed on Schedule 1.1(d).

 

“Labeled Inventory
Partial Assignment Agreement” means the Labeled Inventory Partial Assignment Agreement, dated as of the Closing Date,
by and among Seller, IGI Purchaser, Covis Pharma S.à.r.l., Zug Branch, Covis Injectables S.à.r.l., Zug Branch, and
Covis Pharmaceuticals, Inc., attached as Exhibit C.

 

“Labeling”
(and the correlative terms “Label” and “Labeled”) shall be as defined in Section 201(m) of
the FDCA (21 U.S.C. § 321(m)) as implemented by 21 CFR Part 201, and other comparable foreign Law relating to the subject
matter thereof, including the applicable Product’s label, packaging and package inserts accompanying such Product, and any
other written, printed, or graphic materials accompanying such Product, including patient instructions or patient indication guides.

 

    -4- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

“Laws”
means any federal, state, foreign or local law, common law, statute, ordinance, rule, regulation, code or Governmental Order.

 

“Liabilities”
means any and all Losses, debts, liabilities and obligations, whether accrued or unaccrued, fixed, known or unknown, absolute or
contingent, matured or unmatured or determined or determinable.

 

“Licensed Intellectual
Property” means all of the Intellectual Property that is licensed to Seller under the Intellectual Property Licenses.

 

“Licensed Know-How”
means all Trade Secret Rights that are (a) owned by Seller or licensable by Seller under Section 6.18 of the Asset Purchase Agreement,
dated March 9, 2015, by and among Covis Pharma S.à.r.l., Zug Branch, Covis Injectables S.à.r.l., Zug Branch, Concordia
Pharmaceuticals Inc., Concordia Healthcare Corp. and Covis Pharma Holdings S.à.r.l., in each case immediately after the
Closing and (b) used in or necessary to Exploit the Products.

 

“Licenses”
means all licenses, permits, certificates and other authorizations and approvals pertaining to the Products required by applicable
Laws.

 

“Liens”
means any lien, security interest, mortgage, charge or similar encumbrance.

 

“Loss”
or “Losses” has the meaning set forth in Section 7.1.

 

“Material Adverse
Effect” means an effect, event, fact, occurrence, development, condition or change that individually or considered together
with all other effects, events, facts, occurrences, developments, conditions or changes (i) has or would reasonably be expected
to have a materially adverse effect on the Purchased Assets or their Exploitation, taken as a whole, or (ii) prevents or materially
impedes or delays the consummation by Seller of the transactions contemplated by this Agreement or the Ancillary Agreements, but
does not include any change or adverse effect caused by (a) changes in conditions generally affecting (I) the healthcare industry
or (II) the United States economy as a whole (whether regulatory, legislative or political conditions or securities, credit, financial
or other capital markets conditions); (b) the announcement of this Agreement and the transactions contemplated by this Agreement,
(c) any failure to meet any internal or publicly available projections, forecasts, estimates or predictions with respect to the
Purchased Assets or their Exploitation or (d) changes in geopolitical conditions, the outbreak or escalation of hostilities, any
acts of war, sabotage, terrorism or military actions, or any natural disasters or calamities; provided, however,
that any effect, event, fact, occurrence, development, condition or change referred to in clause (a) or in clause (d) above shall
be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be expected to occur to
the extent that such effect, event, fact, occurrence, development, condition or change has a disproportionate effect on the Purchased
Assets or their Exploitation relative to other Persons engaged in similarly situated businesses, in the industries in which Seller
operates.

 

    -5- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

“NDA”
means a new drug application.

 

“NDC Number”
means the unique identifying number assigned to a drug product, including the labeler code, product code and package code, in connection
with the drug listing requirements of Section 510(j) of the FDCA and applicable FDA rules and regulations.

 

“Non-Assignable
Asset” has the meaning set forth in Section 2.2(a).

 

“Party”
means each of IGI Purchaser, TJL Purchaser and Seller.

 

“Patents”
means all patents and patent applications, together with any extensions, supplemental protection certificates, reexaminations,
reissues, divisions and continuations and foreign counterparts claiming priority to any of the foregoing.

 

“Permitted Encumbrances”
means (i) Liens approved in writing by Purchasers; (ii) statutory Liens arising by operation of Law with respect to a Liability
incurred in the ordinary course of business that is not delinquent or is being contested in good faith by appropriate proceedings;
(iii) Liens and other imperfections of title that do not materially detract from the value or materially impair the use of the
property subject thereto; (iv) Liens for Taxes not yet subject to penalties for nonpayment or that are being contested in good
faith by appropriate proceedings; (v) mechanics’, materialmens’, carriers’, workmens’, warehousemens’,
repairmens’, landlords’ or other like Liens and security obligations that are not delinquent and (vi) Liens arising
in connection with the transactions contemplated by this Agreement. 

 

“Person”
means an individual, a limited liability company, joint venture, a corporation, a partnership, an association, a trust, a division
or operating group of any of the foregoing or any other entity or organization.

 

“Post-Closing
Tax Period” means any Tax period (or portion thereof) beginning after the Closing Date.

 

“Pre-Closing
Tax Period” means any Tax period (or portion thereof) ending on or before the Closing Date.

 

“Proceeding”
has the meaning set forth in Section 8.9(b).

 

“Product Registrations”
means the authorizations from applicable Governmental Authorities (including
NDAs) and comparable regulatory filings (i) granted to Seller by, or applications therefor pending with, any applicable Governmental
Authority (including applications that are in the process of being prepared by Sellers) and (ii) acquired by Seller from a third
party, in each case required to manufacture, commercialize, develop, package, Label, store, use, market, import, export, distribute
and/or sell any of the Products listed on Schedule 1.1(e).

 

    -6- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

“Products”
means the products listed under the heading “Products” in the table set forth on Schedule 1.1(e).

 

“Promotional
Materials” means, collectively, all marketing materials, marketing research data, customer and sales information, product
literature, promotional materials and data, advertising and display materials (including all underlying designs, samples, charts,
diagrams, photos and electronic files related to the foregoing) and all training materials, in each case in whatever form or medium
(e.g., audio, visual, digital or print), to the extent (i) in Seller’s physical possession or control and (ii) of
the portions thereof exclusively related to the Purchased Assets.

 

“Property Taxes”
has the meaning set forth in Section 8.7(b).

 

“Purchase Orders”
means, with respect to IGI Purchaser, the IGI Purchase Orders, and with respect to TJL Purchaser, the TJL Purchase Orders.

 

“Purchase Price”
has the meaning set forth in Section 3.1(a).

 

“Purchased Assets”
means, with respect to IGI Purchaser, the IGI Purchased Assets, with respect to TJL Purchaser, the TJL Purchased Assets, and with
respect to Seller, the IGI Purchased Assets and the TJL Purchased Assets, it being understood that the Purchased
Assets do not include the Excluded Assets.

 

“Purchasers”
has the meaning set forth in the Preamble of this Agreement.

 

“Purchaser FDA
Transfer Letter” means each of the letters from IGI Purchaser and/or TJL Purchaser to the FDA indicating TJL Purchaser’s
acquisition of each Product Registration from Seller and acceptance of the associated regulatory responsibilities.

 

“Purchaser Indemnified
Parties” has the meaning set forth in Section 7.1.

 

“Receipt”
means the receipt for payment of the Purchase Price at Closing, dated as of the Closing Date, attached as Exhibit D hereto.

 

“Regulatory
Documentation” means (a) all regulatory filings and supporting documents (including copies of all correspondence between
Seller and the applicable Governmental Authority), chemistry, manufacturing and controls data and documentation, preclinical and
clinical studies and tests, (b) the NDAs and foreign equivalents and all regulatory files related thereto, current approved Labeling
and any other existing files and dossiers, including the underlying data or information used to support, maintain or obtain marketing
authorization of the underlying Product, (c) all records maintained under record keeping or reporting Laws of the FDA or any other
Governmental Authority, including FDA warning letters, FDA notices of adverse finding letters, FDA audit reports (including any
responses to such reports), any correspondence with any office at the FDA, periodic safety update reports, complaint files, and
annual product quality reviews, (d) the complete complaint, adverse event and medical inquiry filings with respect to the Products
as required by applicable Laws and related to the Purchased Assets, including the Product Registrations and (e) all equivalent,
comparable or analogous documentation with respect to any other country outside the United States, in each of the foregoing clauses
(a) through (e), solely to the extent (i) in Seller’s physical possession or control and (ii) exclusively related to the
Purchased Assets.

 

    -7- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

“Representatives”
means, with respect to any Person, the directors, officers, managers, employees, independent contractors, authorized agents or
consultants of such Person.

 

“Retained Products”
means all products owned by Seller other than the Products, including those set forth on Schedule 1.1(f).

 

“Seller”
has the meaning set forth in the Preamble of this Agreement.

 

“Seller Disclosure
Schedule” has the meaning set forth in Article IV.

 

“Seller FDA
Transfer Letter” means each of the letters from Seller to the FDA indicating Seller’s transfer of the ownership
of each Product Registration to Purchaser.

 

“Seller Indemnified
Parties” has the meaning set forth in Section 7.2.

 

“Shared Contract”
means any Contract binding upon Seller that relates to one or more Products and to one or more Retained Products and is set forth
on Schedule 1.1(g).

 

“Tax”
or “Taxes” means any and all federal, state, local, foreign and other income, gross receipts, sales, use, value-added,
production, ad valorem, transfer, franchise, registration, profits, license, lease, service, service use, withholding, payroll,
employment, unemployment, estimated, excise, severance, environmental, stamp, occupation, premium, property (real or personal),
real property gains, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever, together
with any interest, additions or penalties with respect thereto and any interest in respect of such interest, additions or penalties
determined or assessed by a Taxing Authority.

 

“Tax Return”
includes any return, report, declaration, election, notice, filing, form, statement and other document (whether in tangible, electronic
or other form) and including any amendment, schedule, attachment, supplement, appendix or exhibit thereto, made, prepared, filed
or required to be made, prepared or filed by applicable Laws relating to Taxes.

 

“Taxing Authority”
means any Governmental Authority, body or instrumentality exercising any authority to impose, regulate or administer the imposition
of Taxes.

 

“TJL Assignment
and Assumption Agreement” means the assignment and assumption agreement, dated as of the Closing Date, attached as Exhibit
E to this Agreement.

 

“TJL Assumed
Contracts” has the meaning set forth in Schedule 1.1(h).

 

“TJL Bill of
Sale” means the bill of sale, dated as of the Closing Date, attached as Exhibit F of this Agreement.

 

    -8- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

“TJL Purchase
Orders” has the meaning set forth in Schedule 1.1(h).

 

“TJL Purchased
Assets” means the assets set forth on Schedule 1.1(h), it being understood that the TJL Purchased Assets do not
include the Excluded Assets.

 

“TJL Purchaser”
has the meaning set forth in the Preamble of this Agreement.

 

“Third Party
Claim” has the meaning set forth in Section 7.4(a).

 

“Trade Secret”
means a “Trade Secret” as such term is defined in the Uniform Trade Secrets Act, published in 1979 and amended in 1985.

 

“Trade Secret
Rights” means all rights, anywhere in the world, in or to trade secrets, inventions, discoveries, formulae, know-how,
ideas, processes, designs, data, databases and other proprietary information, in each case, whether or not patentable or copyrightable.

 

“Trademarks”
means all  trademarks, service marks, internet domain names, trade dress, trade names, all applications and registrations
for the foregoing, and all goodwill associated therewith and symbolized thereby, including all renewals of the same.

 

“Transfer Taxes”
means any federal, state, county, local, foreign and other sales, use, transfer, value added, conveyance, documentary transfer,
stamp, recording, registration or other similar Tax (including any notarial fee) imposed in connection with, or otherwise relating
to, the transactions contemplated by this Agreement or the recording of any sale, transfer or assignment of property (or any interest
therein) effected pursuant to this Agreement, but such term shall not include Taxes imposed on or measured by net income of Seller
or Purchasers, or imposed in lieu of such a Tax.

 

“Transition
Services Agreement” means the Transition Services Agreement, dated as of the Closing Date, by and between Seller and
Purchasers, attached as Exhibit G.

 

Section
1.2        Other Definitional Provisions. (a) The words “hereof”,
“herein”, “hereto” and “hereunder” and words of similar import, when used in this Agreement,
shall refer to this Agreement as a whole and not to any particular provision of this Agreement.

 

(b)        The
terms defined in the singular shall have a comparable meaning when used in the plural, and vice versa.

 

    -9- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

(c)        The
terms “dollars” and “$” shall mean United States of America dollars.

 

(d)        The
term “including” shall mean “including, without limitation.”

 

(e)        When
a reference is made in this Agreement to an Article, a Section, an Exhibit or a Schedule, such reference shall be to an Article
of, a Section of, an Exhibit to or a Schedule to, this Agreement unless otherwise indicated.

 

ARTICLE
II

 

PURCHASE
AND SALE

 

Section
2.1        Purchase and Sale of Assets. Upon the terms and subject to the
conditions set forth herein and subject to Section 2.2, at the Closing, Seller shall sell, convey, assign, transfer and
deliver to each Purchaser, as applicable, and each Purchaser, as applicable, shall purchase, acquire and accept from Seller, free
and clear of all Liens, other than Permitted Encumbrances, all of Seller’s right, title and interest in, to and under the
Purchased Assets.

 

Section
2.2        Consents. (a) Notwithstanding Section 2.1, if any of the
Assumed Contracts or other Purchased Assets are not assignable or transferable (each, a “Non-Assignable Asset”)
without the consent of, or waiver by, a third party (each, an “Assignment Consent”), either as a result of
the provisions thereof or applicable Laws, and any of such Assignment Consents are not obtained by Seller on or prior to the Closing
Date, (i) Seller shall continue its efforts pursuant to Section 2.2(b) to obtain the Assignment Consents after Closing,
(ii) this Agreement and the related instruments of transfer shall not constitute an assignment or transfer of such Non-Assignable
Assets and (iii) the applicable Purchaser shall not assume Seller’s rights or obligations under such Non-Assignable Asset
(and such Non-Assignable Asset shall not be included in the Purchased Assets).

 

    -10- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

(b)        Seller
shall use reasonable best efforts from and after the Closing to obtain the consent of the counterparty to any such Non-Assignable
Asset to the assignment (in whole, or with respect to any Shared Contract, in part) of such Non-Assignable Asset to the applicable
Purchaser or to otherwise cooperate with such Purchaser to enter into a reasonable and lawful arrangement, including a new Contract
with such Purchaser on substantially the same terms as exist under the applicable Non-Assignable Asset, to provide such Purchaser
substantially equivalent economic benefits as it would have obtained to the extent the Non-Assignable Asset had been a Purchased
Asset for a period not to exceed the remaining term or useful life of such Non-Assignable Asset, including subcontracting, sublicensing
or subleasing any or all of Seller’s rights and obligations with respect to such Non-Assignable Asset to the extent related
to the Products, to such Purchaser, but only to the extent such cooperation would not result in a breach of the terms of such Non-Assignable
Asset and is not prohibited under applicable Law (it being understood that neither Seller nor such Purchaser
shall be required to expend money, commence any litigation or offer or grant any accommodation (financial or otherwise) to any
third party in connection with its obligations pursuant to this Section 2.2); provided that, in any such alternative
arrangement, such Purchaser shall, solely to the extent related to the Products, (i) be entitled to all benefits thereof, economic
or otherwise, (ii) pay, perform or discharge when due any Liabilities arising thereunder after the Closing but not transferred
to such Purchaser pursuant to this Section 2.2, and provide to Seller all support reasonably necessary or appropriate to
enable Seller to perform its obligations thereunder, (iii) bear all Taxes with respect thereto or arising therefrom and (iv) shall,
severally and jointly with such other Purchaser, indemnify Seller in respect of all Liabilities of Seller in respect of each such
arrangement and underlying Purchased Asset, to the extent such Liabilities have been incurred before the [***] ([***])[***] anniversary
of the Closing. If and when such consents or approvals are obtained or such other required actions have been taken, the assignment
of such Non-Assignable Asset, to the extent related to the Products, to the applicable Purchaser will be effected in accordance
with the terms of this Agreement, and such Non-Assignable Asset will be deemed to be a Purchased Asset and the obligations and
liabilities related thereto will be deemed Assumed Liabilities, in each case, for all purposes of this Agreement.

 

Section
2.3        Excluded Assets. (a) Seller and Purchasers expressly agree and
acknowledge that the Purchased Assets will not include any assets of any kind, nature, character or description (whether real,
personal or mixed, whether tangible or intangible, whether absolute, accrued, contingent, fixed or otherwise, and wherever situated)
that are not expressly included within the definition of Purchased Assets (the “Excluded Assets”).

 

    -11- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

(b)        After
the Closing Date, Purchasers shall take all actions (or shall cause its Affiliates to take all actions) reasonably requested by
Seller to effect the provisions of this Section 2.3, including the return of any Excluded Assets.

 

Section
2.4        Assumption of Liabilities. Upon the terms and subject to the
conditions of this Agreement, each Purchaser agrees, effective at the Closing, to assume and to satisfy and discharge when due
the following Liabilities of Seller (all of such Liabilities other than the Excluded Liabilities being herein collectively referred
to as the “Assumed Liabilities”):

 

(a)        all
Liabilities in respect of Products Exploited by or on behalf of Purchasers on or after the Closing, including Liabilities in respect
of returns, rebates and chargebacks of Products and, to the extent attributable to the period after the Closing Date, payment of
user fees due for the Products under the Prescription Drug User Fee Act, as amended, as further detailed in the Transition Services
Agreement;

 

(b)        all
Liabilities for Taxes relating to the Purchased Assets or the Products with respect to a Post-Closing Tax Period allocated in accordance
with Section 8.7(b);

 

(c)        all
Liabilities for materials and services relating to the Purchased Assets contracted for by Seller in the ordinary course of business
prior to the Closing, but not delivered or supplied until after the Closing, and all Liabilities to customers under the Purchase
Orders;

 

(d)        all
Liabilities under Assumed Contracts, other than any Liability to the extent arising out of, or resulting from, (i) Liabilities
incurred at or prior to Closing, (ii) any event, state of facts, occurrence, circumstance, development or change that arose or
existed prior to Closing or (iii) services performed or Products sold under Assumed Contracts prior to the Closing; and

 

(e)        all
other Liabilities arising on or after the Closing, solely to the extent arising out of, or relating to, the Purchased Assets or
the Products.

 

    -12- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
2.5        Excluded Liabilities. Except to the extent expressly included
in the Assumed Liabilities, Purchasers will not assume or be responsible or liable for any (a) Liabilities arising prior to the
Closing or (b) Liabilities that relate to acts, events, state of facts, occurrence, circumstances, development, change or conditions
that arose or existed prior to the Closing, in each case, of Seller or its Affiliates, including any Liabilities for Taxes with
respect to the Pre-Closing Tax Period allocated in accordance with Section 8.7(b) (collectively, the “Excluded
Liabilities”).

 

ARTICLE
III

 

CLOSING

 

Section
3.1        Purchase Price

 

(a)        At
the Closing, in consideration of the sale and transfer of the Purchased Assets, Purchasers agree to (x) purchase from Seller the
Purchased Assets for an aggregate purchase price consisting of (i) $10,000,000 in cash plus (ii) the Inventory Value (together,
the “Purchase Price”) and (y) assume, satisfy and discharge when due the Assumed Liabilities.

 

(b)        The
Purchase Price shall be paid without reduction for any Transfer Taxes or withholding Taxes imposed by the United States or any
state or possession of the United States. Purchasers shall pay the Purchase Price at the Closing in immediately available funds,
by wire transfer, the wire instructions for which will be specified in written instructions given by Seller to Purchasers.

 

Section
3.2        Closing. The Closing shall take place at the offices of Sullivan & Cromwell LLP,
located at 125 Broad Street, New York, New York 10004, at 10:00 a.m. (New York City time) on the date of this Agreement or
at such other time and place as the Parties may mutually agree in writing. The date on which the Closing occurs is called the
“Closing Date.” The Closing shall be deemed to occur and be effective as of the opening of business on the
Closing Date.

 

    -13- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
3.3        Closing Deliverables.

 

(a)        At
the Closing, Seller shall deliver or cause to be delivered to Purchasers the instruments and documents set forth in Exhibit
H. Promptly after the Closing, but no later than [***] ([***])[***] following the Closing, Seller shall deliver, or cause to
be delivered, to Purchasers physical possession of the Purchased Assets, subject to Section 2.2 and to the extent permitted by
applicable Law. With respect to (i) the Inventory, delivery shall, unless the Parties otherwise mutually agree, be made at the
following address: 4580 Mendenhall Road, Memphis, Tennessee 38141; and (ii) all Books and Records and related items capable
of being delivered in electronic format and all other tangible Purchased Assets, delivery shall, unless the Parties otherwise mutually
agree, be made in an electronic medium to the following address: Teligent Jersey Limited, c/o IGI Laboratories, Inc. 105 Lincoln
Avenue, Buena, NJ 08310.

 

(b)        At
the Closing, each Purchaser, as applicable, shall deliver or cause to be delivered to Seller, the following: (i) the Purchase Price,
as provided in Section 3.1, (ii) the instruments and documents set forth in Exhibit I and (iii) the instruments and
documents set forth in Exhibit J.

 

ARTICLE
IV

 

REPRESENTATIONS
AND WARRANTIES OF SELLER

 

Except as set forth in
the corresponding sections or subsections of the disclosure schedule delivered by Seller to Purchasers prior to entering into this
Agreement (the “Seller Disclosure Schedule”) (it being agreed that disclosure of any item in any section or
subsection of the Seller Disclosure Schedule shall be deemed disclosure with respect to any other section or subsection to which
the relevance of such item is reasonably apparent on its face), Seller hereby represents and warrants to Purchaser as follows:

 

    -14- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
4.1        Organization and Qualification. Seller is a corporation duly
organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and is duly qualified
or licensed to do business and is in good standing in each jurisdiction in which the concept of good standing is recognized and
in which such qualification or licensing is necessary under applicable Laws of such jurisdiction.

 

Section
4.2        Authority; Binding Effect.

 

(a)        Seller
has all requisite corporate power and authority to carry on its business as it is now being conducted and to execute and deliver
this Agreement and each Ancillary Agreement to which it is a party and to perform its obligations hereunder and thereunder. The
execution and delivery by Seller of this Agreement and each such Ancillary Agreement to which it is a party, and the performance
by it of its obligations hereunder and thereunder, have been duly authorized by all requisite corporate action. No approval of
any Affiliate of Seller, nor any of their respective shareholders is necessary for Seller to execute and deliver this Agreement
and each Ancillary Agreement to which it will be a party or perform the transactions contemplated hereby or thereby, other than
any such approval that has been obtained and remains in full force and effect.

 

(b)        This
Agreement and each Ancillary Agreement has been duly executed and delivered by Seller and constitutes a valid and binding obligation
of Seller, in each case enforceable against Seller in accordance with its terms, except as enforcement may be limited by bankruptcy,
insolvency, reorganization, fraudulent conveyance, moratorium or similar laws affecting creditors’ rights generally or by
general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law).

 

Section
4.3        No Conflicts. The execution, delivery and performance of this
Agreement and each Ancillary Agreement by Seller and the consummation of the transactions contemplated hereby and thereby will
not (i) violate any provision of the organizational documents of Seller; (ii) subject to the terms of Section 2.2, conflict
with, or result in the breach of, constitute a default under, result in the termination, cancellation or acceleration (whether
after the giving of notice or the lapse of time or both) of any right or obligation of Seller under, or to a loss of any benefit
to which Seller is entitled under, any Assumed Contract; or (iii) violate or result in a breach of or constitute a default under
any Law or other restriction of any Governmental Authority to which Seller is subject; except, with respect to clauses (ii) and
(iii), for any violations, breaches, conflicts, defaults, terminations, cancellations or accelerations that have not or would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

    -15- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
4.4        Governmental Authorization; Consents. Except as set forth on
Section 4.4 of the Seller Disclosure Schedule, the execution, delivery or performance of the obligations under this Agreement
or any Ancillary Agreement by Seller or the consummation of the transactions by Seller contemplated hereby or thereby, including
the transfer of the Purchased Assets to Purchasers, does not require the consent, approval, waiver or authorizations of, filing
with, notices to, or exemption by, any Governmental Authority, except for consents or approvals that the failure to obtain would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

Section
4.5        Absence of Material Changes. Except as otherwise contemplated
by this Agreement, during the period in which Seller has owned the Purchased Assets to the date of this Agreement, except with
respect to the transactions contemplated by this Agreement and the Ancillary Agreements and the sales process with respect to
the Purchased Assets by Seller:

 

(a)        Seller
operated the Purchased Assets, in all material respects, in the ordinary course of business; and

 

(b)        There
has not been any event, fact, occurrence, development, condition or change that, individually or in the aggregate, has had or would
reasonably be expected to result in a Material Adverse Effect.

 

    -16- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
4.6        No Litigation. As of the date of this Agreement, there is no
Proceeding by or before any Governmental Authority that is pending against or, to the Knowledge of Seller, threatened in writing
against Seller with respect to the Purchased Assets. There is no Governmental Order outstanding against Seller relating primarily
to the Purchased Assets.

 

Section
4.7        Compliance with Laws.

 

(a)        Seller
is conducting, and at all times during the period in which Seller has owned the Purchased Assets, has conducted, its business and
operations as it relates to the Purchased Assets and the Products, in compliance in all material respects with all applicable Laws,
and is not in material violation or default under any authorization of any Governmental Authority as it relates to the Purchased
Assets. At all times during the period Seller has owned the Purchased Assets, all Products sold under the Product Registrations
are, and have been, manufactured and marketed in all material respects in compliance with the specifications and standards contained
in such Product Registrations and in compliance with all applicable Health Care Laws.

 

(b)        As
of the date of this Agreement, Seller possesses and is in compliance with all Licenses necessary for the operation of the Purchased
Assets and Exploitation of the Products as currently conducted by Seller.

 

Section
4.8        Product Registrations; Regulatory Compliance.

 

(a)        A
true and complete list of Product Registrations is set forth on Schedule 1.1(e). Seller is the sole and exclusive owner,
free and clear of any Liens, except for Permitted Encumbrances, of the Product Registrations required for the conduct of its business
as it relates to the Purchased Assets, as currently conducted by Seller, and as of the date of this Agreement, such Product Registrations
are valid and in full force and effect. Excluding the Contracts set forth in Section 4.8(a) of the Seller Disclosure Schedule,
no right of reference has been granted to any Person with respect to any of the Product Registrations.

 

(b)        Seller
has, during the period in which Seller has owned the Purchased Assets, fulfilled and performed, and is performing, all of its material
obligations with respect to the Product Registrations, and no event has occurred that allows, or after notice or lapse of time
would allow, revocation or termination thereof or result in any other impairment of the rights of the holder of any Product Registration.
Seller has not received any written notice, letters or other correspondence from the FDA, or any other Governmental Authority or
Person (i) contesting any of the Product Registrations or (ii) otherwise alleging any violation of Health Care Laws by Seller.
There are no civil, criminal or administrative Proceedings, hearings or other investigations pending or, to the Knowledge of Seller,
threatened, and, to the Knowledge of Seller, no event has occurred during the period in which Seller has owned the Purchased Assets
that could result in a penalty under or the revocation, cancellation, suspension, non-renewal or adverse modification of any Product
Registration.

 

    -17- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

(c)        Seller
has completed and filed all material reports, documents, claims, permits and notices required by any Governmental Authority to
be filed by it in order to maintain the Product Registrations, including drug registration and listing submissions to the FDA.
In each case, as it relates to the Products, to the Knowledge of Seller, no director, officer, employee, or agent of Seller, has
made an untrue statement of a material fact or fraudulent statement to the FDA or any other Governmental Authority, failed to disclose
a material fact required to be disclosed to the FDA or any other Governmental Authority, or committed an act, made a statement,
or failed to make a statement that, at the time such disclosure was made, would reasonably be expected to provide a basis for the
FDA or any other Governmental Authority to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery,
and Illegal Gratuities,” set forth in 56 Fed. Reg. 46191 (Sept. 10, 1991) or any similar policy. As it relates to the Products,
to the Knowledge of Seller, no director, officer, employee, or agent of Seller has engaged in any conduct that has resulted, or
would reasonably be expected to result, in debarments under 21 U.S.C. § 335a(a) or any similar Laws. As it relates to the
Products, to the Knowledge of Seller, neither Seller nor any of its officers, employees, agents or distributors has been convicted
of any crime or engaged in any conduct for which such Person could be excluded from participating in any federal health care programs
under Section 1128 of the Social Security Act of 1935, as amended, or any similar Law or program.

 

(d)        Seller
has not voluntarily or involuntarily initiated, conducted or issued, or caused to be initiated, conducted or issued, nor, to the
Knowledge of Seller, do any circumstances exist that are reasonably likely to give rise to, any recall, field alerts, field corrections,
market withdrawal or replacement, safety alert, warning, “dear doctor” letter, investigator notice, safety alert, or
other notice or action relating to an alleged lack of safety, efficacy or regulatory compliance of any Product.

 

(e)        Seller
has not received any written notice that any Governmental Authority has (i) commenced, or threatened to initiate, any action to
request the recall of any Product sold or intended to be sold by Seller or alleging any violations of any federal, state or local
or any payor “fraud and abuse,” consumer protection and false claims statutes and regulations or any pricing or rebate
reporting requirements, (ii) commenced, or threatened to initiate, any action to enjoin manufacture or distribution of any Product
sold or intended to be sold by Seller or (iii) issued any demand letter, finding of deficiency or non-compliance or adverse inspection
report in respect of any Product.

 

Section
4.9        Intellectual Property.

 

(a)        As
of the date of this Agreement, to the Knowledge of Seller, (i) there is no action or proceeding pending, or any notice of any objection
or claim asserted in writing or threatened by any Person, with respect to or challenging the ownership, validity or enforceability
of any Licensed Intellectual Property, (ii) the rights of Seller under each Intellectual Property License are free and clear
of any Liens, other than Permitted Encumbrances and the terms and conditions of each such Intellectual Property License, and (iii)
none of the Licensed Intellectual Property has been since September 1, 2012, or is, the subject of (A) any pending or, to the Knowledge
of Seller, threatened in writing material adverse claim, judgment, injunction, order, decree or agreement restricting its use in
connection with any Product, or (B) any other pending or, to the Knowledge of Seller, threatened in writing material litigation
or claim of infringement.

 

    -18- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

(b)        To
the Knowledge of Seller, the manufacture, use and Exploitation of the Products, as performed by or on behalf of Seller as of the
date of this Agreement, does not infringe, misappropriate or otherwise violate any Intellectual Property right of any Person.

 

(c)        To
the Knowledge of Seller, except as set forth on Schedule 4.9(c) of the Seller Disclosure Schedule, the Licensed Intellectual
Property and Purchasers’ other rights under this Agreement are all of the material Intellectual Property necessary for or
used by Seller in connection with the manufacture, use and Exploitation of the Products as currently conducted by Seller.

 

(d)        To
the Knowledge of Seller, no Person is infringing, misappropriating or otherwise violating any Licensed Intellectual Property.

 

Section
4.10        Assets. Subject to Section 2.2 and other than (i) the
services provided to Seller pursuant to the Transition Services Agreement, dated April 21, 2015, by and among Covis Pharma S.à.r.l.,
Zug Branch, Covis Injectables S.à.r.l., Zug Branch, Covis Pharmaceuticals, Inc. and Seller, and (ii) the items set forth
on Section 4.10 of the Seller Disclosure Schedule, as of the date of this Agreement, the Purchased Assets and Purchasers’
rights under this Agreement constitute all of the assets and rights of Seller necessary for Purchasers to manufacture, supply,
market, distribute or Exploit the Products immediately after the Closing in substantially the same manner as Seller immediately
prior to the Closing. Seller has good and marketable title to each of the Purchased Assets, free and clear of all Liens, other
than Permitted Encumbrances.

 

Section
4.11        Contracts. Seller has made available to Purchasers a true, complete
and accurate copy of each of the Assumed Contracts, including any and all amendments, supplements or modified thereto or detailed
description of any oral Assumed Contracts. Each Assumed Contract is legal, valid, binding and enforceable against Seller (subject
to applicable bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar laws affecting creditors’
rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or
law)) and is in full force and effect. Neither Seller nor, to the Knowledge of Seller, any other party to an Assumed Contract
is in material breach or violation of, or default under, any of the Assumed Contracts, and, to the Knowledge of Seller, no event
has occurred that, after the giving of notice or with lapse of time, would constitute a material breach or default under any Assumed
Contract by Seller (or, to the Knowledge of Seller, any other party), or result in a termination thereof or would cause or permit
the acceleration thereof by another party under any of the Assumed Contracts. There are no material disputes pending or, to the
Knowledge of Seller, threatened under any Assumed Contract and, to the Knowledge of Seller, no party has communicated any intention
or threat to reduce the prices it will pay pursuant thereto, to terminate or to cancel any Assumed Contract, or has failed to
renew or extend the term of any Assumed Contract upon the expiration of any such term.

 

    -19- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
4.12        Inventory. Except as set forth on Section 4.12 of the
Seller Disclosure Schedule, the Inventory, as of the Closing Date, (i) shall comply with all applicable specifications in all
material respects, (ii) shall have been manufactured in all material respects in accordance with current Good Manufacturing Practices,
as set forth in the United States Code of Federal Regulations and the Product Registrations, (iii) shall not be misbranded or
adulterated, within the meaning of the FDCA, (iv) shall be saleable in the ordinary course of business and fit for the purpose
for which it was procured or manufactured and (v) to the extent the Inventory contains raw materials and work-in-process, such
raw materials and work-in-process shall have been manufactured, handled, maintained, packaged and stored at all times and in all
material respects in compliance with applicable Laws. The values at which such Inventory is carried in the Books and Records of
Seller is consistent with the past business practices of Seller during the period in which it has owned the Purchased Assets.

  

Section
4.13        Product Liability. During the period in which Seller has owned
the Purchased Assets, and, to the Knowledge of Seller, since September 1, 2012, no Proceedings or arbitrations related to product
liability, including those for consumer fraud and economic loss, have been initiated with respect to the Products and, to the
Knowledge of Seller, no such Proceedings or arbitrations have been threatened or filed relating to any of the Products.

 

    -20- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
4.14        Brokers. Other than Bourne Capital Partners, L.L.C., no broker,
finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions
contemplated by this Agreement and the Ancillary Agreements based upon arrangements made by or on behalf of Seller. Seller is
solely responsible for the fees and expenses of Bourne Capital Partners, L.L.C.

 

Section
4.15        Taxes. (a) With respect to the period beginning on April 21,
2015 and ending on the Closing Date, all material Tax Returns required to be filed by Seller with respect to the Purchased Assets
have been or will be filed when due in accordance with all applicable laws; (b) all Taxes shown on such Tax Returns, if any, have
been or will be paid in timely fashion; (c) there is no action, suit, proceeding, investigation, audit or claim now pending with
respect to any Tax with respect to the Purchased Assets that relates to the period beginning on April 21, 2015 and ending on the
Closing Date and that would result in a Lien on the Purchased Assets that would survive the Closing Date; (d) there are no outstanding
agreements extending the statutory period of limitation applicable to any claim for, or the period for the collection or assessment
of, Taxes with respect to the Purchased Assets that relates to the period beginning on April 21, 2015 and ending on the Closing
Date; (e) there are no Liens, other than Permitted Encumbrances, for any Tax on the Purchased Assets that relates to the period
beginning on April 21, 2015 and ending on the Closing Date.

 

    -21- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
4.16        No Other Representations or Warranties. EXCEPT FOR THE REPRESENTATIONS
AND WARRANTIES EXPRESSLY CONTAINED IN THIS ARTICLE IV (AS MODIFIED BY ANY SCHEDULES HERETO), NEITHER SELLER NOR ANY OTHER
PERSON MAKES ANY OTHER EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY WITH RESPECT TO SELLER, THE PURCHASED ASSETS OR THE TRANSACTIONS
CONTEMPLATED BY THIS AGREEMENT, THE ANCILLARY AGREEMENTS, THE ASSUMED LIABILITIES AND ANY OTHER RIGHTS OR OBLIGATIONS TO BE TRANSFERRED
HEREUNDER OR PURSUANT HERETO, AND SELLER DISCLAIMS ANY OTHER REPRESENTATIONS OR WARRANTIES, WHETHER MADE BY SELLER OR ANY OF ITS
AFFILIATES OR REPRESENTATIVES. SELLER MAKES NO REPRESENTATIONS OR WARRANTIES TO PURCHASERS REGARDING THE PROBABLE SUCCESS OR PROFITABILITY
OF THE PURCHASED ASSETS OR THE PRODUCTS.

 

ARTICLE
V

 

REPRESENTATIONS
AND WARRANTIES OF PURCHASER

 

Each Purchaser hereby
represents and warrants to Seller, as to itself only, as follows:

 

Section
5.1        Organization and Qualification. Such Purchaser is a corporation
or company duly organized, validly existing and in good standing under the Laws of its respective jurisdiction and is duly qualified
or licensed to do business and is in good standing in each jurisdiction in which the concept of good standing is recognized.

 

Section
5.2        Authority; Binding Effect. (a) Such Purchaser has all requisite
corporate power and authority to carry on its business as it is now being conducted and to execute and deliver this Agreement
and each Ancillary Agreement to which it is a party and to perform its obligations hereunder and thereunder. The execution and
delivery by such Purchaser of this Agreement and each such Ancillary Agreement to which it is a party, and the performance by
it of its obligations hereunder and thereunder, have been duly authorized by all requisite corporate action.

 

    -22- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

(b)        This
Agreement and each Ancillary Agreement has been duly executed and delivered by such Purchaser and constitutes a valid and binding
obligation of such Purchaser, in each case enforceable against such Purchaser in accordance with its terms, except as enforcement
may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar laws affecting creditors’
rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law).

 

Section
5.3        No Conflicts; Consents. The execution, delivery and performance
of this Agreement and each Ancillary Agreement by such Purchaser and the consummation of the transactions contemplated hereby
and thereby will not (i) violate any provision of the organizational documents of such Purchaser; (ii) conflict with, or result
in a breach of, constitute a default under, result in the termination, cancellation or acceleration (whether after the giving
of notice or the lapse of time or both) of any term or provision of any Contract to which such Purchaser and/or any of its Affiliates
is a party or is subject; or (iii) violate or result in a breach of or constitute a default under any Law or other restriction
of any Governmental Authority to which such Purchaser is subject; except, with respect to clauses (ii) and (iii), for any violations,
breaches, conflicts, defaults, terminations, cancellations or accelerations that would not, individually or in the aggregate,
reasonably be expected to prevent, materially delay or materially impair such Purchaser’s ability to effect the Closing.

 

Section
5.4        Governmental Authorization. The execution and delivery of this
Agreement by such Purchaser does not require the consent or approval of any Governmental Authority, except for consents or approvals
that the failure to obtain would not, individually or in the aggregate, reasonably be expected to prevent, materially delay or
materially impair such Purchaser’s ability to effect the Closing.

 

    -23- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
5.5        No Litigation. There is no Proceeding by or before any Governmental
Authority that is pending or, to the Knowledge of such Purchaser, threatened in writing against such Purchaser that would materially
interfere with the ability of such Purchaser to perform its obligations hereunder.

 

Section
5.6        Condition of the Purchased Assets. EXCEPT AS IT MAY APPLY TO
CLAIMS BY A PURCHASER FOR FRAUD OR INTENTIONAL MISREPRESENTATION, FOR THE SPECIFIC REPRESENTATIONS AND WARRANTIES EXPRESSLY MADE
BY SELLER IN ARTICLE IV OF THIS AGREEMENT AS MODIFIED BY THE SELLER DISCLOSURE SCHEDULE, (I) SUCH PURCHASER ACKNOWLEDGES
AND AGREES THAT SELLER IS NOT MAKING AND HAS NOT MADE ANY REPRESENTATION OR WARRANTY, EXPRESSED OR IMPLIED, AT LAW OR IN EQUITY,
IN RESPECT OF THE PURCHASED ASSETS, SELLER, SELLER’S AFFILIATES OR ANY OF SELLER’S OR ITS AFFILIATES’ RESPECTIVE
BUSINESSES, ASSETS, LIABILITIES, OPERATIONS, PROJECTIONS, FORECASTS, PROSPECTS OR CONDITION (FINANCIAL OR OTHERWISE), INCLUDING
WITH RESPECT TO MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY ASSETS (EXCEPT AS RELATES TO THE REPRESENTATIONS
AND WARRANTIES REGARDING INVENTORY IN SECTION 4.12 OF THIS AGREEMENT), THE NATURE OR EXTENT OF ANY LIABILITIES OR THE PROSPECTS
OF THE PURCHASED ASSETS OR THE PRODUCTS; (II) SUCH PURCHASER SPECIFICALLY DISCLAIMS THAT IT IS RELYING UPON OR HAS RELIED UPON
ANY REPRESENTATIONS, WARRANTIES OR AGREEMENTS THAT MAY HAVE BEEN MADE BY ANY PERSON AND THAT ARE NOT SPECIFICALLY SET FORTH IN
THIS AGREEMENT AND SUBJECT TO THE LIMITED REMEDIES HEREIN PROVIDED, AND ACKNOWLEDGES AND AGREES THAT SELLER HAS SPECIFICALLY DISCLAIMED
AND DOES HEREBY SPECIFICALLY DISCLAIM ANY SUCH OTHER REPRESENTATION OR WARRANTY MADE BY ANY PERSON; AND (III) SUCH PURCHASER IS
ACQUIRING THE PURCHASED ASSETS AND THE ASSUMED LIABILITIES IN “AS IS” CONDITION AND ON A “WHERE IS” BASIS,
SUBJECT ONLY TO THE SPECIFIC REPRESENTATIONS AND WARRANTIES SET FORTH IN ARTICLE IV OF THIS AGREEMENT (AS MODIFIED BY THE
SELLER DISCLOSURE SCHEDULE AND SELLER’S ELECTRONIC ONLINE DATA ROOM), AS FURTHER LIMITED BY THE SPECIFICALLY BARGAINED-FOR
EXCLUSIVE REMEDIES SET FORTH IN ARTICLE VII.

 

    -24- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
5.7        Brokers. No broker, finder or investment banker is entitled to
any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement and
the Ancillary Agreements based upon arrangements made by or on behalf of such Purchaser.

 

ARTICLE
VI

 

COVENANTS

 

Section
6.1        Bulk Transfer Laws.

 

Each Party hereby waives
compliance by each of the other Parties with the requirements and provisions of any “bulk transfer” Laws of any jurisdiction
that may otherwise be applicable with respect to the sale of any or all of the Purchased Assets to Purchasers.

 

    -25- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
6.2        Books and Records. Purchasers will preserve, or cause to be preserved,
the Books and Records and all other books and records relating to Purchasers’ and/or their Affiliates’ distribution
of Products or related regulatory filing and reporting requirements and activities with respect to Products, including, without
limitation, government price reporting (“Distribution Activities”) for applicable periods of time required
by the FDA or FTC or, in any event, for a period not less than [***] ([***])[***] after the Closing Date (except with respect
to government claims not subject to a statute of limitations, such as Medicaid rebate claims, which shall continue for as long
as there is potential for a claim). Purchasers and their Affiliates will cooperate with Seller and its Representatives during
normal business hours and, upon reasonable advance notice, to provide reasonable access to such records maintained by Purchasers
and their Affiliates relating to Purchasers’ and their Affiliates’ Distribution Activities, to provide reports reasonably
requested by Seller regarding such records and information and to permit copying at the expense of Seller or, where reasonably
necessary, to loan original documents relating to the same.

 

Section
6.3        Insurance. As of the Closing Date, the coverage under all insurance
policies related to the Purchased Assets shall continue in force only for the benefit of Seller and not for the benefit of Purchasers
or any of their Affiliates. Purchasers agree to arrange for their own insurance policies with respect to the Purchased Assets
covering the period commencing as of the Closing Date and agree not to seek, through any means, to benefit from any of Seller’s
insurance policies that may provide coverage for claims relating in any way to the Purchased Assets prior to the Closing.

 

Section
6.4        Trade Notification. Seller and Purchasers shall agree on the
method and content of the notifications to customers of the sale of the Purchased Assets to Purchasers within [***] ([***])[***]
following the Closing Date. Seller and Purchasers agree that said notifications are to provide sufficient advance notice of the
sale and the plans associated therewith.

 

    -26- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
6.5        Tax Allocation. The Parties to this Agreement agree that the
amount of the total consideration transferred by Purchasers to Seller pursuant to this Agreement (the “Consideration”)
is and the allocation of the Consideration will be in accordance with the fair market value of the assets and Liabilities transferred
pursuant to this Agreement. The allocation of the Consideration in accordance with the fair market values of the assets and Liabilities
transferred shall be provided by Seller within [***] ([***])[***] following the Closing Date, and Purchasers shall have the right
to review and raise any objections in writing to the proposed allocation during the [***] ([***])[***] period after Purchasers’
receipt thereof. If Purchasers do not notify Seller of a disagreement with the proposed allocation during such [***] ([***])[***]
period, the proposed allocation shall become final. If Purchasers disagree with respect to any item in the allocation, the Parties
shall negotiate in good faith to resolve the dispute. If the Parties are unable to agree on the allocation within [***] ([***])[***]
after the commencement of such good faith negotiations (or such longer period as Seller and Purchasers may agree in writing),
then the parties shall refer such dispute to an independent internationally recognized accounting firm (“Independent
Accountant”) at that time to review the allocation, and make a determination as to the resolution of such allocation.
The determination of the Independent Accountant regarding the allocation shall be delivered as soon as practicable following engagement
of the Independent Accountant, but in no event more than [***] ([***])[***] thereafter, and shall be final, conclusive and binding
upon Seller and Purchasers, and Seller shall revise the allocation accordingly. Seller, on the one hand, and Purchasers on the
other hand, shall each pay one-half of the cost of the Independent Accountant. The finalized allocation shall be binding on Seller
and Purchasers for all Tax reporting purposes, and Seller and Purchasers agree to refrain from taking any position inconsistent
therewith unless required by applicable Law or a final determination of a Taxing Authority.

 

Section
6.6        Tax Treatment. Seller, on one hand, and Purchasers, on the other
hand, agree to treat all payments made either to or for the benefit of the other Party or Parties, as the case may be, under this
Agreement as adjustments to the Purchase Price for Tax purposes to the extent permitted under applicable Tax Law.

 

Section
6.7        FDA Letters.

 

(a)        On
or before [***] ([***])[***] after the Closing Date, Seller shall deliver the Seller FDA Transfer Letters to the FDA providing
notice to the FDA of the transfer of the ownership of the Product Registrations to TJL Purchaser.  On or before [***] ([***])[***]
after the Closing Date, Purchasers shall deliver the Purchaser FDA Transfer Letters to the FDA notifying the FDA of TJL Purchaser’s
ownership of the Product Registrations and its acceptance of the regulatory responsibilities associated with the Product Registrations
from Seller.

 

    -27- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

(b)        Promptly
after the Closing and in any event within [***] ([***])[***] after the Closing, Seller and Purchasers shall make all appropriate
filings and submissions with Governmental Authorities, including the Centers for Medicare & Medicaid Services and the FDA to
register appropriate NDC Numbers in the name of the TJL Purchaser and transfer all regulatory responsibilities, excluding all Excluded
Liabilities attaching thereto of each Product, from Seller to TJL Purchaser.

 

(c)        In
accordance with the foregoing Section 6.7(a) and Section 6.7(b), (i) Seller shall use all commercially reasonable
efforts to complete the transfer of the corresponding Product Registrations as promptly as practicable after the Closing Date to
the benefit of TJL Purchaser and (ii) Purchasers shall use all commercially reasonable efforts to assist Seller in the transfer
of such Product Registrations, accept the transfer of the corresponding Product Registrations and formalize with Sellers and any
applicable Governmental Authority, as promptly as practicable after the Closing Date, all necessary documents. Following the transfer
of the Product Registrations, Sellers shall retain no rights in the Product Registrations or Regulatory Documentation, including
any rights to use or reference.

 

Section
6.8        Regulatory Responsibilities. Except as required by a Party to
comply with applicable Law or to exercise its rights and obligations hereunder or under any Ancillary Agreement, Purchasers, from
and after the Closing, shall have the sole right and responsibility for preparing, obtaining and maintaining all approvals from
Governmental Authorities of competent jurisdiction, for paying user fees due for the Products under the Prescription Drug User
Fee Act (as amended) and for conducting communications with Governmental Authorities of competent jurisdiction, for the Products.

 

    -28- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
6.9        Cooperating. Subject to Section 8.6 and except to the
extent any such disclosure would result, in the reasonable judgment of Seller or Purchasers, as applicable, in (a) the disclosure
of trade secrets of any third parties or violate the terms of any applicable confidentiality provisions, (b) a violation of applicable
Laws, (c) a waiver of the protection of any attorney-client privilege or similar doctrine or (d) the disclosure of any sensitive
or personal information that would expose Seller or Purchasers, as the case may be, to liability, from and after the Closing Date,
and except as set forth in any Ancillary Agreement, each of Seller, on the one hand, and Purchasers, on the other hand, shall
make available to the other during normal business hours and upon reasonable prior written notice, but without unreasonably disrupting
its business, all records to the extent related to the Purchased Assets, the Assumed Liabilities and the Excluded Liabilities
(subject to redactions for commercially sensitive information exclusively related to the Excluded Assets or such other reasonable
measures as the Parties may mutually agree) held by it and reasonably necessary to permit the defense, prosecution or investigation
of any litigation, examination or audit instituted prior to the Closing or that may be instituted thereafter against or by either
Party relating to or arising out of the Exploitation of the Products prior to or after the Closing (other than litigation between
Purchasers or their respective Affiliates, on the one hand, and Seller or its Affiliates, on the other hand, arising out of the
transactions contemplated hereby or by the Ancillary Agreements, with respect to which applicable rules of discovery shall apply),
and shall preserve and retain all such records for the length of time contemplated by its standard record retention policies and
schedules. The Party requesting such cooperation shall pay the reasonable out-of-pocket costs and expenses of providing such cooperation
(including legal fees and disbursements) incurred by any other Party providing such cooperation and by its officers, directors,
employees and agents, and any unrecoverable Transfer Taxes in connection therewith.

 

Section
6.10        Further Assurances. Subject to Section 2.2 and applicable
Law, each of Seller, on the one hand, and Purchasers, on the other hand, shall, at any time or from time to time after the Closing,
at the request and expense of the other, execute and deliver to the other all such instruments and documents or further assurances
as the other may reasonably request in order to (a) vest in Purchasers all of Seller’s right, title and interest in and
to the Purchased Assets as contemplated hereby, (b) effectuate Purchasers’ assumption of the Assumed Liabilities and (c)
grant to each Party all rights contemplated herein to be granted to such Party under the Ancillary Agreements; provided,
however, that after the Closing, apart from such customary further assurances, neither Seller nor Purchasers shall have
any other obligations except as specifically set forth and described herein or in the Ancillary Agreements. Without limitation
of the foregoing, except as expressly set forth herein (including Section 6.8 and Section 6.9) or in the Ancillary
Agreements, neither Seller nor Purchasers shall have any obligation to assist or otherwise participate in the amendment or supplementation
of the Product Registrations or otherwise to participate in any filings or other activities relating to the Product Registrations
other than as necessary to effect the assignment thereof to TJL Purchaser in connection with the Closing pursuant to this Agreement.

 

    -29- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
6.11        Wrong Pockets. For a period of up to [***] ([***])[***] after
the date hereof, if either of the Purchasers, on the one hand, or Seller, on the other hand, becomes aware that any of the Purchased
Assets has not been transferred to Purchasers or that any of the Excluded Assets has been transferred to Purchasers, it shall
promptly (but in any event within [***] ([***])[***]) notify the other and the Parties shall use reasonable best efforts to, as
soon as reasonably practicable, ensure that such property is transferred, with any necessary prior consent or approval, to (a)
the applicable Purchaser, at the expense of the Seller in the case of any Purchased Asset which was not, but should have been,
transferred to such Purchaser at the Closing; or (b) Seller, at the expense of Purchasers in the case of any Excluded Asset which
was, but should not have been, transferred to Purchasers at Closing (it being understood that neither Seller
nor Purchasers shall be required to expend money (except expenses as contemplated by the foregoing clauses (a) or (b),
as applicable), commence any litigation or offer or grant any accommodation (financial or otherwise) to any third party).

 

Section
6.12        Know-How License. Effective as of the Closing, Seller hereby
grants to Purchasers a perpetual, irrevocable, transferable (solely as set forth in the last sentence of this Section 6.12),
sublicensable (solely as set forth in the last sentence of this Section 6.12), non-exclusive, paid-up, royalty-free, worldwide
right and license to use and otherwise exploit the Licensed Know-How solely in connection with developing, commercializing, manufacturing,
using, packaging, marketing, promoting, importing, exporting, researching, transporting, selling and distributing the Products.
Purchasers may (but are not obligated to) transfer the foregoing license, and/or grant sublicenses thereunder, to (a) any of their
Affiliates, and (b) any acquirer of any of the assets or business of Purchasers and their Affiliates relating to any of the Products.

 

    -30- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
6.13      IGI Purchaser Guarantee. IGI Purchaser hereby irrevocably and
unconditionally guarantees to Seller, as a primary obligation, the due and punctual performance of all of TJL Purchaser’s
obligations under this Agreement, including the obligations to (a) perform all of TJL Purchaser’s obligations and assume
all of TJL Purchaser’s liabilities as provided by this Agreement and (b) make payment of all amounts payable by TJL Purchaser
under this Agreement, when and as TJL Purchaser’s payment obligations hereunder shall become due and payable. In case of
a failure of TJL Purchaser to perform its obligations or pay or provide for punctually any such amounts when due and payable (in
accordance with the terms of any extensions or renewals), IGI Purchaser hereby agrees, upon written demand by Seller, to promptly
perform such obligations, or pay or cause to be paid punctually any such amounts when and as the same shall become due and payable.
IGI Purchaser hereby agrees that its obligations under this Section 6.13 constitute a guarantee of payment when due and
not of collection. IGI Purchaser hereby agrees that its obligations under the guarantee set forth in this Section 6.13
shall be irrevocable and unconditional, irrespective of the validity, regularity or enforceability of any obligations hereunder
against TJL Purchaser, the absence of any action to enforce TJL Purchaser’s obligations hereunder or thereunder, any waiver
or consent with respect to any provisions hereof or thereof, the bankruptcy of TJL Purchaser or any circumstance that might otherwise
constitute a legal or equitable discharge or defense of a guarantor. IGI Purchaser hereby waives (i) promptness, presentment,
demand of payment, protest, order and, except as set forth in this Section 6.13, notice of any kind in connection with
this Agreement and the guarantee provided for in this Section 6.13 or (ii) any requirement that Seller exhaust any
right to take any action against TJL Purchaser or any other Person prior to or contemporaneously with proceeding to exercise any
right against IGI Purchaser, pursuant to the guarantee set forth in this Section 6.13. This Section 6.13 is subject
to the provisions of Article VII in all respects.

 

ARTICLE
VII

 

INDEMNIFICATION

 

Section
7.1        Indemnification by Seller. Subject to the provisions of this
Article VII, from and after the Closing, Seller agrees to defend, indemnify and hold harmless Purchasers and their Affiliates,
and, if applicable, their respective directors, officers, agents, employees, successors and assigns (collectively, the “Purchaser
Indemnified Parties”) from and against any and all claims, actions, causes of action, judgments, awards, losses, damages,
penalties or costs (including reasonable attorneys’ fees and other out-of-pocket costs incurred in investigating, preparing
and defending the foregoing) (collectively, a “Loss” or, the “Losses”) to the extent arising
or resulting from (i) any Excluded Liability, (ii) any breach by Seller of any of its covenants or agreements contained in this
Agreement or (iii) any breach of any representation or warranty of Seller contained in this Agreement.

 

    -31- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
7.2        Indemnification by IGI Purchaser. Subject to the provisions of
this Article VII, from and after the Closing, IGI Purchaser agrees to defend, indemnify and hold harmless Seller and its
Affiliates, and, if applicable, their respective directors, officers, agents, employees, successors and assigns (collectively,
the “Seller Indemnified Parties”) from and against any and all Loss to the extent arising or resulting from
(i) any Assumed Liability, (ii) any breach by either Purchaser of any of its respective covenants or agreements in this Agreement,
(iii) any breach of any representation or warranty of either Purchaser contained in this Agreement or (iv) the Exploitation, development,
manufacture, supply, marketing or distribution of the Products following the Closing.

 

Section
7.3        Notice of Claims. (a) If any of the Persons to be indemnified
under this Article VII (the “Indemnified Party”) has suffered or incurred any Loss subject to indemnification
under this Article VII, the Indemnified Party shall so notify the Party responsible for providing indemnification therefor
under this Agreement (the “Indemnifying Party”) promptly in writing describing such Loss, the basis for indemnification
hereunder, the amount or estimated amount of such Loss, if known or reasonably capable of estimation, and the method of computation
of such Loss, all with reasonable particularity and containing a reference to the provisions of this Agreement in respect of which
such Loss shall have occurred. If any action at law or suit in equity is instituted by or against a third party with respect to
which the Indemnified Party intends to seek indemnity under this Article VII, the Indemnified Party shall promptly notify
the Indemnifying Party of such action or suit and tender to the Indemnifying Party the conduct or defense of such action or suit.
A failure by the Indemnified Party to give notice and to tender the conduct or defense of the action or suit in a timely manner
pursuant to this Section 7.3 shall not limit the obligation of the Indemnifying Party under this Article VII, except
(i) to the extent such Indemnifying Party is prejudiced thereby, (ii) to the extent expenses are incurred during the period in
which notice was not provided and (iii) as provided by Section 7.5.

 

    -32- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

(b)        Except
when a notice, report or other filing must be filed immediately pursuant to applicable Law, a Purchaser shall provide notice and
an opportunity to comment to Seller before such Purchaser files any report, notification or filing with any Governmental Authority
or third party in connection with an event that would be reasonably likely to result in a Loss subject to the indemnification provisions
of Section 7.1. In the event such Purchaser is required to file a report, notification or filing immediately, such Purchaser
shall provide simultaneous notice to Seller when it submits such report, notification or filing to the applicable Governmental
Authority.

 

Section
7.4        Third Party Claims. (a) The Indemnifying Party under this Article
VII shall have the right, but not the obligation, to conduct and control, through counsel of its choosing, any third party
Proceeding (a “Third Party Claim”), and the Indemnifying Party may compromise or settle the same, provided
that the Indemnifying Party shall give the Indemnified Party advance notice of any proposed compromise or settlement. No Indemnified
Party may compromise or settle any Third Party Claim for which it is seeking indemnification hereunder without the consent of
the Indemnifying Party. The Indemnifying Party shall permit the Indemnified Party to participate in, but not control, the defense
of any such action or suit through counsel chosen by the Indemnified Party, provided that the fees and expenses of such
counsel shall be borne by the Indemnified Party. If the Indemnifying Party elects not to control or conduct the defense or prosecution
of a Third Party Claim, the Indemnifying Party nevertheless shall have the right to participate in the defense or prosecution
of any Third Party Claim and, at its own expense, to employ counsel of its own choosing for such purpose.

 

(b)        The
Parties hereto shall cooperate in the defense or prosecution of any Third Party Claim, with such cooperation to include (i) the
retention and the provision of the Indemnifying Party records and information that are reasonably relevant to such Third Party
Claim and (ii) making employees available on a mutually convenient basis to provide additional information and explanation of any
material provided hereunder.

 

    -33- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
7.5        Expiration. All representations and warranties made by the Parties
in this Agreement will survive until the [***] anniversary of the Closing Date, except that the representations and warranties
contained in Section 4.1 (Organization and Qualification), Section 4.2 (Authority; Binding Effect),
Section 4.14 (Brokers), Section 5.1 (Organization and Qualification), Section 5.2 (Authority;
Binding Effect) and Section 5.7 (Brokers) (the foregoing Sections, the “Fundamental Representations”)
shall survive indefinitely. Any matter as to which a claim has been asserted by timely notice that is pending or unresolved at
the end of the applicable survival period will continue to be covered by this Article VII, notwithstanding any applicable
statute of limitations, until such matter is finally terminated or otherwise resolved under this Agreement or non-appealable judgment
of an arbitrator, and any amounts payable under this Agreement are finally determined and paid.

 

Section
7.6        Limitations on Indemnification.

 

(a)        Threshold.
Seller shall not be liable, pursuant to Section 7.1(ii), for any Losses suffered by any Purchaser Indemnified Party unless
the aggregate of all Losses suffered by the Purchaser Indemnified Parties exceeds, on a cumulative basis, an amount equal to [***]
percent ([***]%) of the Purchase Price (the “Indemnity Threshold”), in which event Seller shall be required
to pay or be liable for all such Losses in excess of the Indemnity Threshold. IGI Purchaser shall not be liable, pursuant to Section
7.2(ii), for any Losses suffered by the Seller Indemnified Parties unless the aggregate of all Losses suffered by the Seller
Indemnified Parties exceeds, on a cumulative basis, the Indemnity Threshold, and then IGI Purchaser shall be required to pay or
be liable for all such Losses in excess of the Indemnity Threshold.

 

(b)        Cap.
In no event shall Seller be liable to indemnify the Purchaser Indemnified Parties pursuant to Section 7.1 for Losses in
the aggregate in excess of an amount equal to [***] percent ([***]%) of the Purchase Price (the “Cap”), other
than (i) with respect to claims for indemnification pursuant to Section 7.1(iii) for Losses arising out of any breach of
any Fundamental Representations, in which case Seller shall not be liable to indemnify the Purchaser Indemnified Parties for Losses
in the aggregate in excess of an amount equal to the Purchase Price, or (ii) Losses attributable to fraud or intentional misrepresentation
of Seller. In no event shall IGI Purchaser be liable to indemnify the Seller Indemnified Parties pursuant to Section 7.2(iii)
for Losses in the aggregate in excess of the Cap, other than (i) with respect to claims for indemnification pursuant to Section
7.2(iii) for Losses arising out of any breach of any Fundamental Representations, in which case IGI Purchaser shall not be
liable to indemnify the Seller Indemnified Parties for Losses in the aggregate in excess of an amount equal to the Purchase Price,
or (ii) Losses attributable to fraud or intentional misrepresentation of Purchasers.

 

(c)        Mitigation.
The Parties shall cooperate with each other and use commercially reasonable efforts to satisfy their respective common law duties
to mitigate or resolve any Losses that are indemnifiable hereunder, as further provided in Section 7.7 below.

 

(d)        Other
Limitations. If a Party is conducting any defense against a Third Party Claim for which any other Party has sought indemnification
pursuant to Section 7.1 or Section 7.2, as applicable, the fees and expenses incurred during the defense against
such Third Party Claim, including legal costs and expenses, shall constitute Losses for purposes of determining the amount subject
to the Cap pursuant to Section 7.6(b). For purposes of calculating the amount of Losses pursuant to Section 7.1(iii)
or Section 7.2(iii), the representations and warranties in this Agreement shall be read without regard to any qualification
as to “material,” “materiality,” Material Adverse Effect or similar qualifiers.

 

    -34- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

(e)        Exclusion
of Certain Damages. Notwithstanding anything in this Agreement to the contrary, NONE
OF THE PARTIES nor THEIR RESPECTIVE Affiliates shall be liable for any indirect, INCIDENTAL, treble, remote, special, exemplary,
opportunity cost, consequential or punitive damages or damages for, measured by or based on lost profits, loss of revenue or income,
diminution in value, multiple of earnings, profits or cash flows, or other similar measures or for any loss of business reputation
or opportunity THAT ARISES OUT OF OR RELATES TO THIS AGREEMENT OR THE PERFORMANCE OR BREACH HEREOF OF ANY LIABILITY RETAINED OR
ASSUMED HEREUNDER, EXCEPT TO THE EXTENT ANY SUCH DAMAGE OR LOSS WAS A REASONABLY FORESEEABLE CONSEQUENCE OF THE BREACH; PROVIDED,
FURTHER, HOWEVER, THAT THE FOREGOING LIMITATION ON DAMAGES SHALL NOT APPLY TO ANY SUCH DAMAGES (I) THAT ARE ACTUALLY AWARDED
PURSUANT TO A THIRD-PARTY CLAIM OR (II) RESULTING FROM FRAUD OR intentional misrepresentation BY THE INDEMNIFYING PARTY. 

 

Section
7.7        Losses Net of Insurance, Etc.

 

Any indemnifiable claim
with respect to any matter shall be limited to the amount of actual out-of-pocket indemnifiable Losses sustained and incurred by
the Indemnified Party by reason of such matter (and no Indemnifying Party shall have an indemnification payment obligation, nor
be entitled to assert any claim for indemnification, in respect of any contingent liability unless and until such liability becomes
due and payable) net of any insurance proceeds actually received as an offset against such Loss. The Indemnifying Party may require
an Indemnified Party to assign to the Indemnifying Party the rights to seek recovery pursuant to the preceding sentence (to the
extent such rights are capable of assignment); provided, however, that the Indemnifying Party shall then be responsible
for pursuing such claim at its own expense; and provided further, that the Indemnified Party shall cooperate (at
the Indemnifying Party’s expense) with the Indemnifying Party to seek such recovery. If the amount to be netted hereunder
from any payment required under Section 7.1 or Section 7.2 is determined after payment by the Indemnifying Party
of any amount otherwise required to be paid to an Indemnified Party pursuant to this Article VII, the Indemnified Party
shall repay to the Indemnifying Party, promptly after such determination, any amount that the Indemnifying Party would not have
been required to pay pursuant to this Article VII had such determination been made at the time of such payment.

 

    -35- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
7.8        Reimbursement. If an Indemnified Party recovers an amount from
a third party in respect of a Loss that is the subject of indemnification hereunder after all or a portion of such Loss has been
paid by an Indemnifying Party pursuant to this Article VII, the Indemnified Party shall promptly remit to the Indemnifying
Party the amount received from the third party in respect thereof.

 

Section
7.9        Sole Remedy/Waiver. Should the Closing occur, the remedies provided
for in this Article VII shall be the sole and exclusive remedies of any Indemnified Party in respect of this Agreement,
the Ancillary Agreements, the Purchased Assets, the Products, the Excluded Assets, the Assumed Liabilities, the Excluded Liabilities
or the transactions contemplated hereby or by the Ancillary Agreements, other than (a) for actions for specific performance or
other equitable remedies and (b) claims for fraud or intentional misrepresentation. In furtherance of the foregoing, each
Party hereby waives any provision of applicable Law to the extent that it would limit or restrict the agreement contained in this
Section 7.9.

 

ARTICLE
VIII

 

MISCELLANEOUS

 

Section
8.1        Notices. All requests, notices, instructions or other communications
to be given hereunder by one Party to another Party shall be deemed to have been duly given and made if in writing and if served
by personal delivery upon the Party for whom it is intended, if delivered by registered or certified mail, return receipt requested,
by a national courier service or by facsimile or electronic mail transmission (“e-mail”) (provided that such
facsimile or e-mail is promptly confirmed within [***] ([***])[***]by dispatch pursuant to one of the other methods described
herein) to the Person at the address set forth below, or such other address as may be designated in writing hereafter, in the
same manner, by such Person:

 

    -36- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

To Seller:

 

Concordia Pharmaceuticals Inc.,
S.à.r.l., Barbados Branch

[***]

[***]

[***]

Telephone: [***]

Facsimile: [***]

E-mail: [***]

Attn: [***]

 

with a copy
(which shall not constitute notice) to:

 

Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Telephone: (212) 558-7931

Facsimile: (212) 291-9519

E-mail: VeeraraghavanK@sullcrom.com

Attn: Krishna Veeraraghavan

 

to Purchasers:

 

IGI Laboratories, Inc.

[***]

[***]

Telephone: [***]

Facsimile: [***]

E-mail: [***]

Attn: [***]

 

Teligent Jersey Limited

[***]

[***]

Telephone: [***]

Facsimile: [***]

E-mail: [***]

Attn: [***]

 

    -37- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

with a copy (which shall
not constitute notice) to:

 

Mintz Levin Cohn Ferris Glovsky
and Popeo, P.C.

666 Third Avenue

New York, New York 10017

Telephone: (212) 935-3000

Facsimile: (212) 983-3155

E-mail: JIPapernik@mintz.com

Attn: Joel I. Papernik, Esq.

 

Section
8.2        Amendment; Waiver. Any provision of this Agreement may be amended
or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by Purchasers and Seller,
or in the case of a waiver, by the Party against whom the waiver is to be effective. No failure or delay by any Party in exercising
any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude
any other or further exercise thereof or the exercise of any other right, power or privilege.

 

Section
8.3        Successors and Assigns; No Third Party Beneficiaries. No Party
to this Agreement may assign any of its rights or obligations under this Agreement including by sale of stock, by operation of
Law in connection with a merger or by sale of all or substantially all the assets of such Party without the prior written consent
of the other Parties hereto; provided, however, that nothing in the foregoing shall prohibit Purchasers or Seller
from making any assignment (i) to any of its Affiliates so long as such Affiliate agrees in writing to be bound by all of the
terms, conditions and provisions contained in this Agreement; provided further, that no such assignment shall release
Purchasers or Seller, as the case may be, from their obligations under this Agreement; and (ii) to any successors to all or substantially
all of the business and assets of Purchasers or Seller, whether in a merger, consolidation, sale of substantially all assets or
other similar transaction. Any purported assignment, hypothecation or transfer in breach of this Section 8.3 shall be null
and void. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors
and permitted assigns. Except as set forth in Article VII, this Agreement is for the sole benefit of the parties hereto
and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon
any other Person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this
Agreement.

 

    -38- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
8.4        Entire Agreement. This Agreement and the Ancillary Agreements
(in each case, including all Schedules and Exhibits hereto and thereto) contain the entire agreement between the Parties with
respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such
matters, except for (i) the Confidentiality Agreement, which will remain in full force and effect for the term provided for therein,
and (ii) any written agreement of the Parties that expressly provides that it is not superseded by this Agreement. In the event
of a conflict between the provisions of this Agreement and the provisions of the Confidentiality Agreement, the provisions of
this Agreement shall control.

 

Section
8.5        Parties in Interest. Nothing in this Agreement, express or implied,
is intended to confer upon any Person other than Purchasers, Seller or their successors or permitted assigns, any rights or remedies
under or by reason of this Agreement, except that the provisions of Article VII shall inure to the benefit of the Purchaser
Indemnified Parties and Seller Indemnified Parties, as applicable.

 

Section
8.6        Confidential Information. All confidential information made available
to Purchasers, their Affiliates and their respective Representatives with respect to Seller, its Affiliates, the Purchased Assets
or the Assumed Liabilities shall be treated in accordance with the Confidentiality Agreement, which shall remain in full force
and effect in accordance with its terms notwithstanding the termination of this Agreement.

 

    -39- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
8.7        Expenses, Transfer Taxes and Property Taxes. (a) All costs and
expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be borne by the Party incurring
such expenses. Notwithstanding the foregoing, all Transfer Taxes imposed by the United States, or any state or possession of the
United States, or Jersey shall be paid by Purchasers and all Transfer Taxes imposed by Barbados or Luxembourg shall be paid by
Seller.

 

(b)        In
the case of any taxable period that includes (but does not end on) the Closing Date, (i) real, personal and intangible property
Taxes and similar Taxes imposed with respect to the Purchased Assets (“Property Taxes”) shall be allocated between
the Pre-Closing Tax Period and the Post-Closing Tax Period on a per diem basis, and (ii) all other Taxes imposed with respect
to the Purchased Assets (other than Transfer Taxes subject to the second sentence of Section 8.7(a)) shall be allocated
between the Pre-Closing Tax Period and the Post-Closing Tax Period as though the taxable period terminated as of the effective
time of the Closing. Seller, on the one hand, and Purchasers, on the other hand, shall promptly reimburse each other in accordance
with such allocation for any such Property Taxes which any Party is required to pay under applicable Law.

 

Section
8.8        Schedules. The disclosure of any matter in any Schedule to this
Agreement shall be deemed to be a disclosure with respect to any other section or subsection of this Agreement with respect to
which its relevance is reasonably apparent on its face for all purposes of this Agreement. Notwithstanding anything in this Agreement
to the contrary, the parties hereto agree that the inclusion of an item in the Seller Disclosure Schedule as an exception to any
representation, warranty or other part of this Agreement will not be deemed an admission that such item represents a material
exception or a material fact, event or circumstance, that such item is required to be disclosed by this Agreement or that such
item has had or would reasonably be expected to have a Material Adverse Effect.

 

    -40- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
8.9        Governing Law; Jurisdiction. (a) This Agreement and the Ancillary
Agreements and their negotiation, execution, performance or non-performance, interpretation, termination, construction and all
claims or causes of action (whether in contract, in tort, at law or otherwise) that may be based upon, arise out of, or relate
to this Agreement, the Ancillary Agreements or the transactions contemplated hereby or thereby (including any claim or cause of
action based upon, arising out of or related to any representation or warranty made in connection with this Agreement or the Ancillary
Agreements or as an inducement to enter into this Agreement or the Ancillary Agreements), shall be exclusively governed by, and
construed in accordance with, the Laws of the State of Delaware, regardless of Laws that might otherwise govern under any applicable
conflict of Laws principles.

 

(b)        Any
claim, demand, suit, action, cause of action, or proceeding (whether in contract, in tort, at law or otherwise) (each, a “Proceeding”)
based upon, arising out of, or related to this Agreement and the Ancillary Agreements and their negotiation, execution, performance,
non-performance, interpretation, termination, construction or the transactions contemplated by the Agreement or the Ancillary Agreements
shall be heard and determined in the Court of Chancery in the City of Wilmington, New Castle County, Delaware or, in the event
such court lacks subject matter jurisdiction, the United States District Court sitting in Wilmington, Delaware or, in the event
such federal district court lacks subject matter jurisdiction, then in the Superior Court in the City of Wilmington, New Castle
County, Delaware. The Parties hereby irrevocably submit to the exclusive jurisdiction and venue of such courts in any such Proceeding
and irrevocably and unconditionally waive the defense of an inconvenient forum, or lack of jurisdiction to the maintenance of any
such Proceeding. The consents to jurisdiction and venue set forth herein shall not constitute general consents to service of process
in the State of Delaware and shall have no effect for any purpose except as provided in this Section 8.9 and shall not be
deemed to confer rights on any Person other than the Parties. Each Party agrees that the service of process upon such Party in
any Proceeding arising out of or relating to this Agreement or the Ancillary Agreements shall be effective if notice is given by
overnight courier at the address set forth in Section 8.1. Each of the Parties also agrees that any final, non-appealable
judgment against a Party in connection with any Proceeding arising out of or relating to this Agreement shall be conclusive and
binding on such Party and that such award or judgment may be enforced in any court of competent jurisdiction, either within or
outside of the United States. A certified or exemplified copy of such award or judgment shall be conclusive evidence of the fact
and amount of such award or judgment.

 

    -41- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
8.10     WAIVER OF JURY TRIAL. TO THE FULLEST EXTENT PERMITTED BY LAW,
THE PARTIES HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY PROCEEDING (whether
in contract, in tort, at law or otherwise) BASED UPON, ARISING OUT OF OR RELATED TO THIS AGREEMENT, THE ANCILLARY AGREEMENTS
OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT OR THE ANCILLARY AGREEMENTS. THE SCOPE OF THIS WAIVER IS INTENDED TO
BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS AGREEMENT,
INCLUDING WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS.
THE PARTIES ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY
RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE
DEALINGS. THE PARTIES FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT EACH KNOWINGLY
AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE, MEANING THAT
IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS
OR MODIFICATIONS TO THIS AGREEMENT OR THE ANCILLARY AGREEMENTS. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN
CONSENT TO A TRIAL BY THE COURT.

 

    -42- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
8.11      Counterparts. This Agreement may be executed in one or more
counterparts (including by facsimile or electronic .pdf submission), each of which shall be deemed an original, and all of which
shall constitute one and the same agreement and shall become effective when one or more counterparts have been signed by each
of the Parties and delivered (by telecopy or otherwise) to the other Party, it being understood that each Party need not sign
the same counterpart.

 

Section
8.12    Headings. The heading references herein and the table of contents
hereto are for convenience purposes only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

Section
8.13     Severability. The provisions of this Agreement shall be deemed
severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other
provisions hereof. If any term or other provision of this Agreement, or the application thereof to any Person or any circumstance,
is invalid, illegal or unenforceable, (a) a suitable and equitable provision shall be substituted therefor in order to carry out,
so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder
of this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity,
illegality or unenforceability, nor shall such invalidity, illegality or unenforceability affect the validity or enforceability
of such provision, or the application thereof, in any other jurisdiction.

 

    -43- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

Section
8.14      Mutual Drafting. The Parties are sophisticated and have been represented
by lawyers throughout the transactions contemplated hereby who have carefully negotiated the provisions hereof. As a consequence,
the Parties do not intend that the presumptions set forth in Laws or rules relating to the interpretation of contracts against
the drafter of any particular clause should be applied to this Agreement or any Schedule or Exhibit hereto, and therefore, waive
their effects.

 

[Remainder of Page Intentionally Left
Blank]

 

    -44- 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

     

    

 

IN WITNESS WHEREOF,
the Parties have executed or caused this Agreement to be executed as of the date first written above.

 

	 	CONCORDIA PHARMACEUTICALS INC., S.À.R.L., BARBADOS BRANCH
	 	 	 	 
	 	By:	/s/ Erin O’Neil / Neil Smith	 
	 	Name:	Erin O’Neil / Neil Smith	 
	 	Title:	COO / VP Finance	 
	 	 	 
	 	IGI LABORATORIES, INC.	 
	 	 	 	 
	 	By:	/s/ Jason Grenfell-Gardner	 
	 	Name:	 Jason Grenfell-Gardner	 
	 	Title:	President & CEO	 
	 	 	 
	 	TELIGENT JERSEY LIMITED	 
	 	 	 	 
	 	By:	/s/ Jason Grenfell-Gardner	 
	 	Name:	Jason Grenfell-Gardner	 
	 	Title:	President	 

  

    [Signature Page to Asset Purchase Agreement]

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.EX-10.1

 Exhibit 10.1 
  

					
	

	 		 	         Zimmer Pte Ltd

 
         315 Alexandra Road

        #03-03 Sime Darby Business Center

        Singapore 159944

 Change in Control Severance Agreement 

This Change in Control Severance Agreement (“Agreement”) is made by and between Zimmer Pte Ltd (“Employer” or
“Company” as case may be) and Yi Sang-Uk (“Executive”). 
 Recitals 

 

	(A)	The Company considers it essential to the best interests of its ultimate shareholders to foster the continuous employment of key management personnel. 

 

	(B)	The Company and the Board recognize that, as is the case with many publicly held corporations, the possibility of a Change in Control in the Ultimate Parent Company exists and that such a possibility, and the
uncertainty and questions that it may raise among management, may result in the departure or distraction of management personnel to the detriment of the Company and its shareholders. 

 

	(C)	The Board has determined that appropriate steps should be taken to reinforce and encourage the continued attention and dedication of members of the Company’s management, including the Executive, to their assigned
duties without distraction in the face of potentially disturbing circumstances arising from the possibility of a Change in Control. 

  

	(D)	The parties intend that no amount or benefit will be payable under this Agreement unless a termination of the Executive’s employment with the Company occurs following a Change in Control, or is deemed to have
occurred following a Change in Control, as provided in this Agreement. 

 Defined terms as used herein and not defined elsewhere in
this Agreement, shall have the meaning as described to them in Annex 1 to this Agreement. 
  

	1.	Term of Agreement 

 This Agreement will commence on the date stated below and will
continue in effect through December 31, 2015. Beginning on January 1, 2016, and each subsequent January 1, the term of this Agreement will automatically be extended for one additional year, unless either party gives the other party
written notice not to extend this Agreement at least 30 days before the extension would otherwise become effective or unless a Change in Control occurs. If a Change in Control occurs during the term of this Agreement, this Agreement will continue in
effect for a period of 24 months from the end of the month in which the Change in Control occurs. Notwithstanding the foregoing provisions of this Article, this Agreement will terminate on the Executive’s retirement date. 

 
 2
 / 13 
 Change in Control Severance Agreement 

 
  

	2.	Compensation other than Severance Payments 

  

	2.1	Compensation Previously Earned 

 If the Executive’s employment is terminated for any
reason following a Change in Control and during the term of this Agreement, the Company will pay the Executive’s salary accrued through the Date of Termination, at the rate in effect at the time the Notice of Termination is given, together with
all other compensation and benefits payable to the Executive through the Date of Termination under the terms of any compensation or benefit plan, program, or arrangement maintained by the Company during that period. 

 

	2.2	Normal Post-Termination Compensation and Benefits. 

 Except as provided in
Section 3.1, if the Executive’s employment is terminated for any reason following a Change in Control and during the term of this Agreement, the Company will pay the Executive the normal compensation and benefits payable to the Executive
under the terms of the Company’s compensation or benefit plans, programs, and arrangements, as in effect immediately prior to the Change in Control, including but not limited to the Non-Competition Period Payments (if any). This provision does
not restrict the Company’s right to amend, modify, or terminate any plan, program, or arrangement prior to a Change in Control. 
  

	2.3	No Duplication. 

 Notwithstanding any other provision of this Agreement to the contrary,
the Executive will not be entitled to duplicate benefits or compensation under this Agreement and the terms of any other plan, program, or arrangement maintained by the Company or any affiliate. 

 

	3.	Severance Payments 

  

	3.1	Payment Triggers 

 In addition to the payments as set out in Section 2 above, but in
lieu of any other severance compensation or benefits to which the Executive may otherwise be entitled under any plan, program, policy, or arrangement of the Company, the Company will pay the Executive the Severance Payments described in
Section 3.2 upon termination of the Executive’s employment following a Change in Control and during the term of this Agreement, unless the termination is (1) by the Company for Cause, (2) by reason of the Executive’s death,
or (3) by the Executive without Good Reason. 
 For purposes of this Section 3.1, the Executive’s employment will be deemed to
have been terminated following a Change in Control by the Company without Cause or by the Executive with Good Reason if (1) the Executive’s employment is terminated without Cause prior to a Change in Control at the direction of a Person
who has entered into an agreement with the Ultimate Parent Company, the consummation of which will constitute a Change in Control; or (2) the Executive terminates his employment with Good Reason prior to a Change in Control (determined by
treating a Potential Change in Control as a Change in Control in applying the definition of Good Reason), if the circumstance or event that constitutes Good Reason occurs at the direction of such a Person. 

 
 3
 / 13 
 Change in Control Severance Agreement 

 
  

 The Severance Payments described in this Section 3 are subject to the conditions stated
in Section 4 below and shall be reduced in part or in their totality if and to the extent the Severance Payments were, at the time of their payment, to be deemed a golden parachute or similar arrangement prohibited under the laws where the
Company is incorporated and has its registered office or the costs associated with the Severance Payments could no longer be booked as expenditures in the Company’s profit and loss statement. 

 

	3.2	Severance Payments. 

 The following are the Severance Payments referenced in
Section 3.1: 
  

	 	(a)	Lump Sum Severance Payment 

 In lieu of any further salary payments to the Executive for
periods after the Date of Termination, and in lieu of any severance benefits otherwise payable to the Executive, the Company will pay to the Executive, in accordance with Section 3.3, a lump sum severance payment, in cash, equal to (a) two
times the sum of (1) the higher of the Executive’s annual base salary in effect immediately prior to the event or circumstance upon which the Notice of Termination is based or in effect immediately prior to the Change in Control, plus
(2) the amount of the Executive’s target annual bonus entitlement under the Cash Incentive Plan (or any other bonus plan of the Company then in effect) as in effect immediately prior to the event or circumstance giving rise to the Notice
of Termination, less (b) the amount of any statutory payment to which the Executive is entitled related to any statutory notice period and (c) any mandatory statutory deductions and tax withholding, if applicable. If the Board determines
that it is not workable to determine the amount that the Executive’s target bonus would have been for the year in which the Notice of Termination was given, then, for purposes of this paragraph (a), the Executive’s target annual bonus
entitlement will be the average of annual bonus paid to the Executive with respect to the three years immediately prior to the year in which the Notice of Termination was given. 

 

	 	(b)	Options and Restricted Shares 

 All outstanding Options will become immediately vested
and exercisable (to the extent not yet vested and exercisable as of the Date of Termination). To the extent not otherwise provided under the written agreement evidencing the grant of any restricted Shares to the Executive, all outstanding Shares
that have been granted to the Executive subject to restrictions that, as of the Date of Termination, have not yet lapsed will lapse automatically upon the Date of Termination, and the Executive will own those Shares free and clear of all such
restrictions. Notwithstanding the foregoing, Options and restricted Shares remain subject to any forfeiture or clawback claims under the applicable option plan or award agreement. 

 

	3.3	Time of Payment 

 Except as otherwise expressly provided in Section 3.2, payments
provided for in that Section will be made as follows: 
 No later than the fifth business day following the Date of Termination, the Company
will pay to the Executive an estimate, as determined by the Company in good faith, of 90% of the payments under Section 3.2 (a) to which the Executive is clearly entitled. 

 
 4
 / 13 
 Change in Control Severance Agreement 

 
  

 The Company will pay to the Executive the remainder of the payments due to him under
Section 3.2 not later than 90 business days after the Date of Termination. 
 At the time that payment is made under this
Section 3.3, the Company will provide the Executive with a written statement setting forth the manner in which all of the payments to him under this Agreement were calculated and the basis for the calculations. 

 

	3.4	Outplacement Services 

 For a period not to exceed six (6) months following the Date
of Termination, the Company will provide the Executive with reasonable outplacement services consistent with past practices of the Company prior to the Change in Control or, if no past practice has been established prior to the Change in Control,
consistent with the prevailing practice of medical device companies in the industry. 
  

	4.	The Executive’s Covenants 

  

	4.1	Confidentiality, Non-Competition and Non-Solicitation Agreement 

 The Executive herewith
acknowledges and affirms his continuing obligations under the Confidentiality, Non-Competition and Non-Solicitation Agreement he executed and re-affirms his agreement to honor the obligations as set forth therein. 

 

	4.2	General Release 

 The Executive agrees that, notwithstanding any other provision of this
Agreement, the Executive will not be eligible for any Severance Payments under this Agreement unless the Executive timely signs a General Release in substantially the form attached to this Agreement as Annex 2. The Executive will be given 30 days to
consider the terms of the General Release. If the Executive does not return the executed General Release to the Company by the end of the 30 day period that failure will be deemed a refusal to sign, and the Executive will not be entitled to receive
any Severance Payments under this Agreement. 
  

	5.	Notices 

 For the purpose of this Agreement, notices and all other communications
provided for in the Agreement will be in writing and will be deemed to have been duly given when delivered or mailed by registered mail, return receipt requested, addressed to the respective addresses set forth below, or to such other address as
either party may furnish to the other in writing in accordance with this Section 5, except that notice of change of address will be effective only upon actual receipt: 

To the Company: 
 Zimmer Pte Ltd

 Attention: Regional Vice President, Legal and Compliance, Asia Pacific 

315 Alexandra Road 
 Sime Darby
Business Centre #05-03 
 Singapore 159944 

 
 5
 / 13 
 Change in Control Severance Agreement 

 
  

 With a copy to: 

Zimmer Biomet Holdings, Inc. 

Attention: General Counsel 
 345
East Main Street 
 Warsaw, Indiana 46580 

United States of America 
 To the
Executive: 
 Yi-Sang Uk 
  

							
		 	  
	 		 	
				
		 	  
	 		 	
				
		 	  
	 		 	
				
		 	  
	 		 	

  

	6.	Miscellaneous 

 This Agreement constitutes and expresses the entire agreement between the
Parties pertaining to the subject matter contained herein and supersedes all prior and contemporaneous oral or written agreements, representations, understandings and the like between the Parties. 

This Agreement may not be modified, amended, altered or supplemented, in whole or in part, except by a written agreement signed by the Parties.

 If any provision of this Agreement is found by any competent authority to be void, invalid or unenforceable, such provision shall be
deemed to be deleted from this Agreement and the remaining provisions of this Agreement shall continue in full force. In this event, the Agreement shall be construed, and, if necessary, amended in a way to give effect to, or to approximate, or to
achieve a result which is as close as legally possible to the result intended by the provision hereof determined to be void, illegal or unenforceable. 

This Agreement may be executed in counterparts, each of which shall be deemed an original, but both of which when taken together will
constitute one and the same agreement. 
  

	7.	Governing Law and Jurisdiction 

 This Agreement shall be governed by, interpreted and
construed in accordance with the substantive laws of Singapore. 
 The Parties irrevocably agree that the courts of Singapore are to have
jurisdiction to settle any disputes which may arise out of or in connection with this Agreement and that, accordingly, any legal action or proceedings arising out of or in connection with this Agreement may be brought in those courts and the Parties
irrevocably submit to the jurisdiction of those courts. 

 
 6
 / 13 
 Change in Control Severance Agreement 

 
  

	8.	Third Party Rights 

 Any person other than the Company and the Executive has no right
under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore, to enforce any term of, or enjoy any benefit under, this Agreement. 

This Agreement enters into force on the later date set-out below. 
  

					
	Zimmer Pte Ltd	 		 	Executive
			
	 /s/ Benedict L.T. Seah
	 		 	 /s/ Yi Sang-Uk

	Benedict L.T. Seah	 		 	Yi Sang-Uk
	Regional Vice President,	 		 	
	Human Resources	 		 	
			
	Date: August 13, 2015	 		 	Date: August 18, 2015

 
 7
 / 13 
 Change in Control Severance Agreement 

 
  

 Annex 1: Definitions 

“Beneficial Owner” has the meaning stated in Rule 13d-3 under the Exchange Act.

 “Board” means the Board of Directors of the Ultimate Parent Company. 

“Cash Incentive Plan” means the Ultimate Parent Company’s Executive Performance Incentive Plan. 

“Cause” for termination by the Company of the Executive’s employment, after any Change in Control, means (1) the
willful and continued failure by the Executive to substantially perform the Executive’s duties with the Company (other than any such failure resulting from the Executive’s incapacity due to physical or mental illness or any such actual or
anticipated failure after the issuance of a Notice of Termination for Good Reason by the Executive) for a period of at least 30 consecutive days after a written demand for substantial performance is delivered to the Executive by the Company, which
demand specifically identifies the manner in which the Company believes that the Executive has not substantially performed the Executive’s duties; (2) the Executive willfully engages in conduct that is demonstrably and materially injurious
to the Company, the Ultimate Parent Company or its subsidiaries, monetarily or otherwise; or (3) the Executive is convicted of a criminal offense. 

A “Change in Control” will be deemed to have occurred if any of the following events occur: 

 

	 	(a)	any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Ultimate Parent Company (not including in the securities beneficially owned by that Person any securities acquired directly
from the Ultimate Parent Company or its affiliates) representing 20% or more of the combined voting power of the Ultimate Parent Company’s then outstanding securities; or 

 

	 	(b)	during any period of two consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of the period constitute the Board and any new director (other than a
director designated by a Person who has entered into an agreement with the Ultimate Parent Company to effect a transaction described in clause (a), (c) or (d) of this paragraph whose election by the Board or nomination for election by the
Ultimate Parent Company’s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was
previously approved), cease for any reason to constitute a majority of the Board; or 

  

	 	(c)	 the shareholders of the Ultimate Parent Company approve a merger or consolidation of the Ultimate Parent Company with any other corporation, other
than (A) a merger or consolidation that would result in the voting securities of the Ultimate Parent Company outstanding immediately prior to the merger or consolidation continuing to represent (either by remaining outstanding or by being
converted into voting securities of the surviving entity), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Ultimate Parent Company, at least 75% of the combined voting
power of the voting securities of the Ultimate Parent Company 

 
 8
 / 13 
 Change in Control Severance Agreement 

 
  

	 	
or the surviving entity outstanding immediately after the merger or consolidation; or (B) a merger or consolidation effected to implement a recapitalization of the Ultimate Parent Company
(or similar transaction) in which no Person acquires more than 50% of the combined voting power of the Ultimate Parent Company’s then outstanding securities; or 

 

	 	(d)	the shareholders of the Ultimate Parent Company approve a plan of complete liquidation of the Ultimate Parent Company or an agreement for the sale or disposition by the Ultimate Parent Company of all or substantially
all the Ultimate Parent Company’s assets. 

 Notwithstanding the foregoing, a Change in Control will not include any
event, circumstance, or transaction occurring during the six-month period following a Potential Change in Control that results from the action of any entity or group that includes, is affiliated with, or is wholly or partly controlled by the
Executive; provided, further, that such an action will not be taken into account for this purpose if it occurs within a six-month period following a Potential Change in Control resulting from the action of any entity or group that does not include
the Executive. 
 “Date of Termination” means the date on which the notice of termination under the Employment Agreement has
lapsed. 
 “Employment Agreement” means the letter of appointment dated June 1, 2015, including the additional terms
and conditions of employment and the appendices attached thereto, which together form the terms and conditions of employment. 

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended from time to time, and interpretive rules and
regulations. 
 “Good Reason” for termination by the Executive of the Executive’s employment means the occurrence
(without the Executive’s express written consent) of any one of the following acts by the Company, or failures by the Company to act following a Change in Control: 
  

	 	(a)	the assignment to the Executive of any duties inconsistent with the Executive’s status as an executive officer of the Company or a substantial adverse alteration in the nature or status of the Executive’s
responsibilities from those in effect immediately prior to a Change in Control; 

  

	 	(b)	the Company’s failure, without the Executive’s consent, to pay to the Executive any portion of the Executive’s current compensation (which means, for purposes of this paragraph (b), the Executive’s
annual base salary as in effect on the date of this Agreement, or as it may be increased from time to time, and the awards earned pursuant to the Cash Incentive Plan) or to pay to the Executive any portion of an installment of deferred compensation
under any deferred compensation program of the Company, within 30 days of the date the compensation is due; 

  

	 	(c)	 the Company’s failure to continue in effect any compensation plan in which the Executive participates immediately prior to a Change in Control,
which plan is material to the Executive’s total compensation, including, but not limited to, the Cash Incentive Plan and the Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan or any substitute plans adopted prior to the Change in Control,

 
 9
 / 13 
 Change in Control Severance Agreement 

 
  

	 	
unless an equitable arrangement (embodied in an ongoing substitute or alternative plan) has been made with respect to that plan, or the Company’s failure to continue the Executive’s
participation in such a plan (or in a substitute or alternative plan) on a basis not materially less favorable, both in terms of the amount of benefits provided and the level of the Executive’s participation relative to other participants, as
existed at the time of the Change in Control. 

 Notwithstanding the foregoing, the occurrence of an event that would otherwise
constitute Good Reason will cease to be an event constituting Good Reason if the Executive does not timely provide a Notice of Termination to the Company within 120 days of the date on which the Executive first becomes aware (or reasonably should
have become aware) of the occurrence of that event. 
 “Non-Competition Period Payments” has the meaning as defined in the
Confidentiality, Non-Competition and Non-Solicitation Agreement between the Company and the Executive. 
 “Notice of
Termination” means the notice provided for under Section 8 of the additional terms and conditions of employment that form a part of the Employment Agreement. 

“Options” means options to purchase Shares awarded to the Executive during his employment with the Company. 

“Person” has the meaning stated in section 3(a)(9) of the Exchange Act, as modified and used in sections 13(d) and 14(d) of
the Exchange Act; however, a Person will not include (1) the Ultimate Parent Company or any of its subsidiaries, (2) a trustee or other fiduciary holding securities under an employee benefit plan of the Ultimate Parent Company or any of
its subsidiaries, (3) an underwriter temporarily holding securities pursuant to an offering of those securities, or (4) a corporation owned, directly or indirectly, by the stockholders of the Ultimate Parent Company in substantially the
same proportions as their ownership of stock of the Ultimate Parent Company. 
 “Potential Change in Control” will be deemed
to have occurred if any one of the following events occurs: 
  

	 	(a)	the Ultimate Parent Company enters into an agreement, the consummation of which would result in the occurrence of a Change in Control; 

 

	 	(b)	the Ultimate Parent Company or any Person publicly announces an intention to take or to consider taking actions that, if consummated, would constitute a Change in Control; 

 

	 	(c)	any Person who is or becomes the Beneficial Owner, directly or indirectly, of securities of the Ultimate Parent Company representing 10% or more of the combined voting power of the Ultimate Parent Company’s then
outstanding securities, increases that Person’s beneficial ownership of those securities by 5% or more over the percentage so owned by that Person on the date of this Agreement; or 

 

	 	(d)	the Board adopts a resolution to the effect that, for purposes of this Agreement, a Potential Change in Control has occurred. 

 
 10
 / 13 
 Change in Control Severance Agreement 

 
  

 “Shares” means shares of the common stock, $0.01 par value, of the Ultimate
Parent Company. 
 “Severance Payments” means the payments described in Section 3.2. 

“Ultimate Parent Company” means Zimmer Biomet Holdings, Inc., a Delaware corporation, and any successor to its business and/or
assets. 

 
 11
 / 13 
 Change in Control Severance Agreement 

 
  

 Annex 2 

GENERAL RELEASE 
  

											
	Name:	 	  
	 		 	Notification Date:	 	  
	 	

 Zimmer Pte Ltd (the “Company”) and/or Zimmer Biomet Holdings, Inc. (the “Ultimate Parent Company”) has
offered me certain severance benefits (the “Severance Benefits”) pursuant to a Change in Control Severance Agreement (“Agreement”) between the Company and me. I will only be able to receive the Severance Benefits in consideration
for my signing this General Release. 
 The Company has advised me of, and I acknowledge the following: 

I have 30 calendar days (the “Review Period”) from the date I receive this General Release to consider and sign it. If I do not return this signed
General Release by the end of the Review Period (i.e., by INSERT DATE), the Company will consider this my refusal to sign, and I will not receive the Severance Benefits. If I choose to sign this General Release prior to expiration of the Review
Period, I thereby waive my right to review for the full time period allowed. If I sign this General Release and am age 40 or older as of the date of my signing, it will not be effective for a period of seven calendar days thereafter, during which
time I may change my mind and revoke my signature. To revoke my signature, I must notify the Ultimate Parent Company in writing at Zimmer Biomet Holdings, Inc., 345 East Main Street, Warsaw, IN, 46580, Attention: General Counsel, within seven
calendar days of the date I signed this General Release. 
 By signing this General Release I am giving up, to the fullest extent permitted by law, my right
to sue the Company and any of its affiliates, parent companies and subsidiaries, and its and their past and present officers, directors, employees, and agents (collectively, the “Released Parties”) based upon any act or event occurring
prior to my signing this General Release. Without limitation, and again to the fullest extent permitted by law, I specifically release the Company from any and all claims arising out of my employment and termination, up to and including the date of
my signing of this General Release, including claims based on discrimination under anti-discrimination laws and any and all applicable laws. I acknowledge and agree that I have received all compensation to which I am entitled from the Released
Parties other than the above-referenced Severance Benefits (which remain subject to my entering into this General Release) and agree that I am not eligible to receive any additional form of compensation under any Released Party’s pay, bonus,
commission, or incentive policy or program. I further agree that although I am not precluded by this Agreement from filing an administrative charge with an applicable civil rights commission, I specifically and expressly waive any rights to receive,
directly or indirectly, any monetary damages or other monies from the filing of such charge. 
 I agree, as a condition of receiving the Severance Benefits,
and subject to any rights and obligations I may have under applicable law (including, but not limited to, my right to file and participate in the investigation of an administrative charge of the type described above and any non-waivable rights I may
have to make disclosures specifically allowed or required by applicable law), that I will not make negative comments about or otherwise disparage or try to injure the reputation of any of the Released Parties. I agree to refrain from making negative
statements about any Released Party and/or its methods of doing business, management practices, policies, and the quality of its services or products. I acknowledge and agree that this restriction applies to all forms of communication including such
things as oral statements, written statements, e-mail, text messages, comments on blogs or any other form of electronic or other type of communication. 

 
 12
 / 13 
 Change in Control Severance Agreement 

 
  

 For the sake of clarification, and subject to any non-waivable rights as described above, I acknowledge that
this General Release shall not affect my legal obligation to protect the confidentiality of the Released Parties’ information or any of my other obligations under any confidentiality, intellectual property, non-competition, and/or
non-solicitation agreement that I have entered into with the Company or with any of the other Released Parties. 
 As a condition of receiving the Severance
Benefits I agree that for a period of 90 calendar days beginning with my separation date I shall make myself reasonably available to respond to inquiries from the Released Parties related to carrying out an orderly transition of business following
my termination of employment. I agree that I will provide the Company’s General Counsel or his or her delegate two contact telephone numbers at which I can be reached, either in person or by message, and will update that contact information
within 24 hours if it changes. I further agree that I will return such calls from any of the Released Parties no later than the end of the business day immediately following the date of the call, and will provide information responsive to the
request to the best of my ability. I understand and acknowledge that my agreement to promptly and fully respond to such inquiries is a material condition of my eligibility for the Severance Benefits, and further understand and agree that in the
event I do not cooperate as described herein, I will be immediately obligated to repay to the Company the entire gross amount of my Severance Benefits. 

By signing this General Release, I affirm that I have provided complete and truthful information in response to all inquiries (the “Inquiries”) made
by any of the Released Parties and any investigating authorities in connection with any governmental investigation of any of the Released Parties or litigation involving any of the Released Parties. By signing this General Release, I further affirm
that I have disclosed to the Ultimate Parent Company’s General Counsel or his or her delegate any and all concerns I may have had arising from or related to my employment regarding potential material violations of applicable law and/or the
Company’s Code of Conduct. I agree, by signing the General Release, that if it is later determined that I knowingly provided materially misleading or untruthful information in response to any such Inquiries or failed to disclose during my
employment any potential material violations of applicable law or the Company’s Code of Conduct of which I was aware, I will be immediately obligated to repay to the Company the entire gross amount of my Severance Benefits. 

I agree to cooperate with any of the Released Parties in response to any governmental investigation. I acknowledge that in connection with my job
responsibilities with any of the Released Parties I may have obtained or been privy to information that could be relevant to its or their defense of Company-related lawsuits currently pending or which may be asserted against it or them. I
agree to make myself reasonably available for providing such information and, to the extent necessary, testimony. I understand that the Company will reimburse any reasonable out- of-pocket expenses I may incur in providing this cooperation. I
further understand that the Company will compensate me for time spent on such assistance at an hourly rate based on my base salary as of my termination date, with time spent rounded to the nearest quarter hour for billing purposes. Any such payment
will be reported to me as required under applicable law, and I agree that I will be responsible for any resulting tax liability. 
 By signing this General
Release, I am NOT giving up my right to appeal a denial of a claim for benefits submitted under my medical or dental coverage, life insurance or disability program maintained by the Company. Also, I am NOT giving up my right to file for unemployment

 
 13
 / 13 
 Change in Control Severance Agreement 

 
  

 
insurance benefits at the appropriate time if I so choose, and my signing of this General Release will NOT affect my rights, if any, to coverage by Workers’ Compensation insurance. In
addition, this General Release will not affect any benefits to which I am entitled under the Agreement or any claim arising out of the enforcement of the Agreement. 

This General Release shall be governed by, interpreted and construed in accordance with the substantive laws of Singapore. 

I irrevocably agree that the courts of Singapore are to have jurisdiction to settle any disputes which may arise out of or in connection with this General
Release and that, accordingly, any legal action or proceedings arising out of or in connection with this General Release may be brought in those courts and I irrevocably submit to the jurisdiction of those courts. 

My signature below acknowledges that I have read the above, understand what I am signing, and am acting of my own free will. The Company has advised me to
consult with an attorney and any other advisors of my choice prior to signing this General Release. 
  

											
	SIGNATURE	 	  
	 		 	DATE	 	  
	 	
						
	PRINT NAME

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]